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Einleitung 
Reproduktionsimmunologie 
Ende des 18. Jahrhunderts wiesen die Gebrüder Hunter durch Wachsausguss 
nach, dass kindlicher und mütterlicher Kreislauf voneinander getrennt sind und 
nicht, wie bis dahin angenommen, ein kontinuierlicher Blutfluss von der Mutter 
zum Kind existiert. Die Austauschprozesse an der fetomaternalen Grenzzone 
sind seitdem Gegenstand des wissenschaftlichen Interesses. Der Immunologe 
und Nobelpreisträger Sir Peter Medawar richtete –ein Jahr vor der ersten 
geglückten Organtransplantation- 1953 den Blick auf das immunologische 
Paradox, dass der Fetus, obwohl er jeweils zur Hälfte mütterliche und väterliche 
Gene trägt, vom mütterlichen Immunsystem toleriert wird13. Dies widersprach 
grundlegend der damaligen Vorstellung der Selbst-Fremd-Erkennung und 
begründete die Forschungsrichtung der Reproduktionsimmunologie. Die 
Schwangerschaft ist damit ein natürliches, erfolgreiches Modell 
immunologischer Toleranz.  
 
Beim Aufbau der fetomaternalen Grenzfläche wachsen fetale Zellen (sog. 
Trophoblasten) in die mütterliche Uterusschleimhaut ein, verschmelzen dabei 
miteinander, arrodieren mütterliche Blutgefäße und bilden in der reifen 
Plazenta die Auskleidung eines mütterlichen Blutsees16. Das trophoblastäre 
Synzytium ist also gleichermaßen fetales Epithel wie plazentares Endothel und 
interagiert mit mütterlichen Leukozyten15.  
 
Das mütterliche Immunsystem akzeptiert jedoch nicht einfach passiv das fetale 
Gewebe, sondern immunologische Mechanismen sind zentral an der Invasion 
des Trophoblasten in die mütterliche Dezidua beteiligt und formen die 
fetomaternale Grenzfläche. Dieses immunologische Milieu im Bereich der 
fetomaternalen Grenzzone trägt entscheidend zum Schwangerschaftserfolg bei.  
 
Dem Immunsystem kommt in allen Organen die Aufgabe zu, einen 
physiologischen Grundzustand zu erhalten und im Falle einer Infektion das 
Pathogen zielgerichtet zu bekämpfen ohne jedoch das Organ selbst zu 
schädigen. Dies gilt auch für die fetomaternale Grenzzone. Immunologische 
Mechanismen sind hier jedoch so zentral in die plazentare Architektur und 
Entwicklung verwoben sind, dass eine manifeste Infektion oftmals eine 
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bleibende Schädigung der Plazentafunktion und damit eine Gefährdung des 
weiteren Schwangerschaftsverlaufs nach sich zieht.  
 
Eine genauere Kenntnis der immunologischen Mechanismen im Bereich der 
fetomaternalen Grenzzone kann Hinweise auf die Pathogenese von 
Plazentaerkankungen liefern, die eine hohe perinatale Morbidität bedingen. Zu 
diesen Erkrankungen zählen die hypertensiven Schwangerschaftserkrankungen 
ebenso wie die fetomaternale Transfusion, aber auch die intrauterine 
Wachstumsretardierung und der intrauterine Fruchttod. 
 
Die Frage immunologischer Toleranz ist auch in der Kanzerogenese und in der 
Etablierung des Tumormikromilieus von entscheidender Bedeutung9. Die 
Entstehung und immunologische Etablierung eines malignen Tumors ist die 
gemeinsame Endstrecke eines letztendlich ungerichteten Prozesses. Die 
Charakteristika einer malignen Erkrankung sind daher in hohem Maße 
individuell. Ausdruck dessen ist die zunehmende Hinwendung zu 
individualisierten Krebstherapien (sog. targeted therapies) wie sie z.B. auch 
immuntherapeutische Ansätze darstellen8. Der spezifische Aufbau 
immunologischer Toleranz an der Tumor-Stroma Grenzfläche ist auf Grund der 
großen interindividuellen Unterschiede im humanen System nur schwer 
nachzuvollziehen. Demgegenüber verläuft der Aufbau des spezifischen 
immunologischen Mikromilieus an der fetomaternalen Grenzfläche entlang 
geordneter Bahnen, deren Erforschung allgemeine Prinzipien der 
Toleranzentwicklung im humanen System zu Tage fördern könnte. Die 
vorliegende Habilitationsschrift widmet sich Mechanismen immunologischer 
Toleranz und ihrer Durchbrechung am Plazenta- und Tumor-Modell. 
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Plazentation 
Plazentation als invasiver Prozess  
Der kindliche Anteil der Plazenta, der Trophoblast, differenziert sich in zwei 
Schichten. Der Zytotrophoblast (ZT) umgibt am Beginn der Implantation die 
Blastozyste wie eine Schale. Der zuvorderst in die Uterusschleimhaut 
eindringende Anteil des Trophoblasten verliert seine Zellgrenzen und 
verschmilzt zu einem Synzytium (Synzytiotrophoblast, ST). Der ST dringt aktiv 
in das mütterliche Endometrium ein und löst Umbauprozesse aus, die zur 
Arrosion mütterlicher Kapillaren und zur Bildung blutgefüllter Lakunen führen. 
Damit hat der kindliche Anteil der Plazenta ca. ab dem 10. embryonalen 
Entwicklungstag Anschluss an das mütterliche Gefäßsystem gefunden. Die 
Grenzfläche und weitere Invasionsfront bildet dabei der Synzytiotrophoblast. 
Die Zytotrophoblastzellen stellen dessen Wachstumsreservoir dar. 
Abb 1. Implantation 10-11. Tag  
 
Ab dem 10. Entwicklungstag hat die invadierende Blastozyste mit der umgebenden 
Trophoblastenschale die mütterlichen Blutgefäße erreicht. Es beginnt der Aufbau der 
fetomaternalen Grenzzone. Adhäsion, Invasion und Wachstum werden im Wechselspiel zwischen 
Trophoblast und mütterlichen Zellen gesteuert. (Abbildung adaptiert nach 16) 
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Die humane Plazenta ist durch eine extrem tiefe Infiltration des mütterlichen 
Stromas (Dezidua) durch den Trophoblasten gekennzeichnet. Kein anderes 
höheres Säugetier (Eutheriae) besitzt eine solche enge Verzahnung von 
kindlichem und mütterlichen Gewebe15. Tief in der mütterlichen Dezidua finden 
sich trophoblastäre Zellnester, die sog. extravillösen Trophoblasten (EVT). 
Trophoblastzellen sind sekretorisch hochaktiv und bilden neben dem bekannten 
„Schwangerschaftshormon“ βHCG eine Vielzahl weiterer Signalproteine 
darunter auch immunaktive Moleküle wie z.B. Zytokine und Chemokine und 
formen damit ihre immunologische Umgebung (Abbildung 3).  
 
Ziel dieses invasiven Prozesses ist es, Anschluss an den mütterlichen 
Blutkreislauf zu gewinnen und einen geregelten Stoffaustausch über die 
Plazentaschranke aufzubauen (Abbildung 2). Eine angepasste Regulation des 
Blutflusses an der fetomaternalen Grenzfläche ist eine der wichtigsten 
Determinanten einer über 40 Wochen entwicklungsfähigen Plazenta. In diesem 
Invasions- und Arrosionsprozess wird der Trophoblast unterstützt vom 
spezifischen immunologischen Milieu, das die immunkompetenten Zellen der 
fetomaternalen Grenzzone aufbauen16. 
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Abb 2. Plazentaentwicklung und Aufbau der fetomaternalen Austauschzone 
 
A: Histologische Entwicklung der Plazenta von links nach rechts. Die verschiedenen Stadien (0-4) 
entwickeln sich nacheinander und treten nie zum gleichen Zeitpunkt auf. Am Ende der 
Entwicklung steht die reife Plazenta.  
B: Schematische Darstellung des Baus einer ausgereiften Haftzotte am Ende der 
Schwangerschaft.  
C: Mikroskopische Struktur der Plazentaschranke am Ende der Schwangerschaft. Die 
Plazentarschranke reduziert sich an der dünnsten Stelle (Blauer Pfeil) auf den kernlosen 
Synzytiotrophoblasten, die vereinigte Basalmembran und das Endothel. Es kommt zu einer 
direkten Interaktion zwischen kindlichem Trophoblasten und mütterlichen Blutzellen 
(Abbildungen adaptiert nach 5) 
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Immunanatomie der fetomaternalen Grenzzone  
In der Dezidua selbst findet sich eine dichte Population immunkompetenter 
Zellen. Zudem spielt das plazenta-spezifisches Zyto- und Chemokinnetzwerk, 
welches durch diese Zellen konstituiert wird, eine zentrale Rolle (Abbildung 3). 
Eine eigentliche organspezifische Infektabwehr lässt sich nur unter 
Rekrutierung externer Effektorzellen bewerkstelligen und stört massiv das 
plazentare Immunmilieu. Der gravide Uterus ist damit – ebenso wie z.B. die 
vordere Augenkammer - eine immun-privilegierte Zone, in der die Balance 
zwischen „Organerhalt“ und „Infektabwehr“ extrem in Richtung „Organerhalt“ 
verschoben ist. In der vorderen Augenkammer gelingt z.B. ein allogenes 
Korneatransplantat unter sterilen Bedingungen, ohne dass es zu einer 
Abstoßungsreaktion kommt, während immunologische Gefahrensignale z.B. 
durch eine manifeste Infektion zum Immunzellinflux und oft zum permanenten 
Funktionsverlust der Kornea d.h. zur Erblindung führen25.  
Abb 3. Immun-Architektur der fetomaternalen Austauschzone 
 
Der Trophoblast kommt in direkten Kontakt mit mütterlichem Blut im intervillösen Raum. In der 
Dezidua findet sich ein spezielles zelluläres immunologisches Milieu. Dargestellt ist eine Auswahl 
der zellulären Komponenten und ihre Hauptsignalmoleküle. (Darstellung angelehnt an15) 
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Uterine Natürl iche Killerzel len 
CD56+ Zellen sog. natürlichen Killerzellen (NK-Zellen) stellen eine 
Hauptkomponente des angeborenen Immunsystems dar. Sie zerstören -ohne 
Erkennen eines spezifischen Antigens- jene somatischen Zellen, deren 
Antigenpräsentations-Moleküle (HLA-Moleküle) genetisch „fremd“ kodiert, 
infektionsbedingt funktionsgestört oder durch anhaftende Antikörper markiert 
sind. Die schnelle und nicht-antigenabhängige Vernichtung solcher Zellen stellt 
einen wichtigen Schutz gegen Viruserkrankungen dar, birgt aber ebenfalls die 
Gefahr der Auto-Immunität. Die zytotoxischen Mechanismen der NK-Zellen sind 
daher sehr strikt reguliert und ihre Ausreifung erfordert ein spezifisches, z.B. 
durch Zytokine und Chemokine geformtes immunologisches Milieu. Neben 
ihren zytotoxischen Fähigkeiten sind sie jedoch auch selbst wichtige 
Produzenten immunologischer Botenstoffe. 
Uterine NK-Zellen (uNK Zellen), die etwa 70% der Immunzellen an der 
fetomaternalen Grenzzone ausmachen, stellen eine, durch das deziduale 
immunologische Milieu geprägte, Sonderform dar, die nur sehr wenig mit NK-
Zellen des peripheren Blutes gemeinsam haben20.  
uNK Zellen sind deutlich weniger zytotoxisch und deutlich mehr sekretorisch 
aktiv. Ein Grund dieser unterschiedlichen Entwicklung von CD56+ Zellen an der 
Dezidua ist auch jene spezielle trophoblastäre Form von antigenpräsentierenden 
Molekülen (HLA-Molekülen), die die zytotoxische Aktivität der NK-Zellen 
hemmen. Hier ist v.a. HLA-G zu nennen15. Lytisch tätig werden uNK Zellen v.a 
im Rahmen des Umbaus der Spiralarterien17. Die Bezeichnung „Killerzelle“ und 
v.a. eine Gleichsetzung mit den ansonsten so bezeichneten Zellen des 
peripheren Blutes beschreibt die bislang bekannten physiologischen 
Eigenschaften der uNK-Zellen jedenfalls nur sehr unzureichend10. Die Sekretion 
von Interferon-γ durch CD56+ Zellen, scheint beim Aufbau der plazentaren 
Immun-Architektur eine entscheidende Rolle zu spielen. Daneben sezernieren 
diese Zellen auch größere Mengen anderer vasoaktiver Substanzen wie z.B. 
vascular endothelial growth factor (VEGF), die ihrerseits bei der Vaskularisation 
der Plazenta eine entscheidende Rolle spielen18. 
Glanduläre Epithelzellen 
An der Immun-Architektur der Plazenta entscheidend beteiligt sind ebenfalls 
glanduläre Epithelzellen11. Sie sezernieren in z.T. sehr großen Mengen lokal 
immunaktive Substanzen wie z.B. Galektine und Glycodelin. Beide Moleküle 
sind Teil der glykosilierungsabhängigen Immunzell-Interakation19. Galektine 
sind eine Gruppe evulotorisch hochkonservierter, kohlehydrat-bindender 
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Proteine, die spezifische Kohlehydratmuster in angepasste Immunantworten 
übersetzen helfen. Es konnte beispielsweise gezeigt werden, dass Galektin 3, 
wenn es mit N-Glycan komplexiert, die Aktivierbarkeit von T-Zellen inhibiert. 
Dies erfolgt durch eine Reduktion der Rezeptordichte auf der Oberfläche von T-
Zellen7.  
Glycodelin 
Glycodelin (auch placental protein 14; PP14) ist ein sezerniertes Glykoprotein, 
das zur Großfamilie der Lipocaline gehört. In unterschiedlicher Glykosilierung 
kommt es vor allem in den glandulären Epithelzellen des Endometriums und der 
Dezidua, aber auch im Seminalplasma des männlichen Ejakulates sowie in 
Ovarien, Eileitern und der weiblichen Brust vor21. Die Sekretion der Gycodeline 
ist im weiblichen Körper strikt abhängig vom monatlichen Anstieg der 
Progesteronkonzentration in der zweiten Zyklushälfte bzw. in der 
Frühschwangerschaft. In Uterusspülungen während des weiblichen Zyklus ist 
Glycodelin lediglich ab der mittleren Sekretionsphase im sog. 
„Implantationsfenster“ nachweisbar. Dann jedoch in einer hohen Konzentration 
von bis zu  12 mg/l. Im Falle einer Schwangerschaft steigert sich die Glycodelin-
Konzentration in der Amnionflüssigkeit – durch Sekretion aus dezidualen 
Drüsenzellen – bis zu einem Wert von 125 mg/l in der 12. 
Schwangerschaftswoche. Desweiteren exprimieren maligne gynäkologische 
Tumore Glycodelin in unterschiedlicher Konzentration. Ein Beispiel hierfür ist, 
neben dem Endometrium-Karzinom, das Ovarial-Karzinom, in dem Glycodelin 
mit gleicher Proteinstruktur aber unterschiedlicher Glykosilierung sezerniert 
wird. Glycodelin hat eine deutliche immunmodulatorisch Potenz. Glycodelin hat 
daher weitreichende Auswirkungen auf das lokale immunologische Milieu. Dies 
gilt sowohl für die zelluläre Zusammensetzung als auch für das Chemo- und 
Zytokinprofil14, 22. 
Zytokine und Chemokine 
Zytokine nehmen Einfluss auf die Implantation sowie die fetale Entwicklung und 
Differenzierung. Zu Beginn der Zytokinforschung fokussierte man sich auf die 
Zytokinsekretion durch T-Zellen. Es konnte nachgewiesen werden, dass CD4+ T-
Helfer Zellen abhängig von der Art der Infektion unterschiedliche Zytokine 
produzieren können und nannte zwei experimentell gut zu unterscheidenden 
Pole der Immunantwort „Th1“ und „Th2“. Th1-Zellen sezernieren Zytokine wie 
Interleukin (IL-)-2, Tumornekrose Faktor (TNF)-beta und Interferon-γ. Th2-
Zellen sezernieren IL-4, IL-5 und IL-10. Beide, Th1- und Th2-Zellen können u.a. 
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IL-3, -6, -12, -13, TNF-alpha und GM-CSF freisetzen. Th1-Zytokine begleiten 
zytotoxische Immunreaktionen. Klassischerweise als Antwort auf eine virale 
Infektion werden dabei infizierte Zellen durch zytotoxische T-Zellen zerstört. 
Th2-Zytokine verstärken auf der anderen Seite die Antikörperproduktion 
(insbesondere IgE) sowie die Proliferation und Funktion der Eosinophilen, was 
die adäquate Immunreaktion z.B. auf einen Parasitenbefall darstellt. Th2-
Antworten unterdrücken Th1-Antworten und umgekehrt. Wegmann und 
Mitarbeiter entwickelten die Theorie einer Balance zwischen Th1/Th2-Zytokinen 
und betonten, dass das fetale Überleben von einer Inhibierung der Th1-Antwort 
durch Th2-Zytokine abhängt28. In den folgenden Jahren haben sich viele 
Forschungsarbeiten darauf fokussiert, den Einfluss von (infekt-induzierten) Th1-
Zytokinen auf das Abortgeschehen darzulegen. Obwohl diese Studien gezeigt 
haben, dass Zytokine einzigartige und wichtige Effekte in der Schwangerschaft 
ausüben, hat sich das Th1/Th2 Paradigma gewandelt. Zytokinnetzwerke sind in 
hohem Maße synergistisch und redundant aufgebaut und die Untersuchung 
einzelner Zytokine liefert oftmals keine eindeutigen Ergebnisse. Die ehemals 
dogmatische Theorie einer Veränderung der Th1/Th2 Balance in der normalen 
und gestörten Schwangerschaft ist dadurch deutlich vielschichtiger geworden. 
Th1-vermittelte Autoimmunerkrankungen (z.B. die rheumatoide Arthritis) 
bessern sich oftmals in der Schwangerschaft, während Th2 vermittelte (z.B. der 
systemische Lupus erythematodes) sich in der Schwangerschaft oftmals 
verschlechtern. Neuere Untersuchungen sehen hierin jedoch eher ein 
Epiphänomen eines veränderten Hormon- und Zytokinhaushalts, als einen 
Beweis dafür, dass ein systemisches Th2-Zytokinmuster essentiell für das 
erfolgreiche Austragen einer Schwangerschaft ist.  
Trophoblast 
Der Trophoblast exprimiert Pathogen-Erkennungs-Rezeptoren (u.a. sog. Toll-
Like Rezeptoren). Diese phylogenetisch sehr alten Rezeptoren - sie finden sich 
schon im Immunsystem der Fruchtfliege - erkennen charakteristische 
Bestandteile von Erregern und veranlassen trophoblastäre Zellen, eine gewebs- 
und erreger-spezifische Immunantwort auszulösen12. Diese Rezeptoren sind 
bildlich gesprochen die „Schalter“, die bei einer manifesten Infektion die 
Infektabwehr in Gang setzen. Sie werden v.a. in den Zellnestern des 
extravillösen Trophoblasten exprimiert, so dass lediglich Infektionen tieferer 
Schichten der Dezidua eine Immunantwort nach sich ziehen1. Im Ruhezustand 
sezernieren die trophoblastären Zellen jedoch Zytokine und lokal aktive 
Chemokine und tragen auf ihrer Oberfläche ein spezifisches Muster 
   11 
 
antigenpräsentierender Moleküle (z.B. HLA-G). Dieses prägt klassische 
Immunzellen so, dass sie die Implantation und Invasion unterstützen und 
steuern. 
Antigenpräsentierende Zellen 
Dendritische Zellen (DC) besetzen eine zentrale Schaltstelle des Immunsystems 
und können einerseits antigenspezifische zytotoxische T-Zell Immunantworten 
induzieren und andererseits im steady state für immunologische Toleranz 
sorgen3, 24. Es ist daher nicht verwunderlich, dass DC auch in der Dezidua eine 
große Zellpopulation darstellen. DC nehmen konstant Fragmente apoptotisch 
zugrunde gegangener Zellen auf und präsentieren deren Antigene, MHC-
restringiert, auf ihrer Oberfläche. Sie präsentieren diese (auch fetalen) Antigene 
in einem immunologischen Kontext, der antigen-spezifische Immunantworten, 
z.B. durch die Generierung regulatorischer T-Zellen, unterdrückt. Bei einer 
Infektion kommen jedoch DC in Kontakt mit Gefahrensignalen, die eine radikale 
Zustandsänderung bewirken. Aktivierte DC wandern in regionäre Lymphknoten 
und kommen dort in Kontakt mit Effektorzellen des adaptiven Immunsystems. 
Sie präsentieren das aufgenommene Antigen in einer Weise, die diese 
Effektorzellen (z.B. zytotoxische T-Zellen) zur klonalen Expansion anregt und 
welche ihrerseits im infizierten Organ die betroffenen Zellen zielgerichtet 
zerstören können. Im „steady state“ tragen deziduale DC wesentlich zur 
physiologischen Immun-Architektur der Plazenta bei4. 
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Eigene Ergebnisse 
Dendritische Zellen  
Physiologie 
Schnurr M, Then F, Galambos P, Scholz C, Siegmund B, Endres S, Eigler A.  
Extracellular ATP and TNF-alpha synergize in the activation and maturation of 
human dendritic cells.  
J Immunol. 2000; 165:4704-4709.  
 
Ob dendritische Zellen einen immunogenen oder tolerogenen Phänotyp 
annehmen, entscheidet sich je nach dem, welches Gefahrensignal sie 
registrieren. Die Charakteristik des Gefahrensignals bedingt neben dem 
spezifischen Antigen dann eine angepasste Immunantwort. In diesem 
Zusammenhang konnten wir die DC-aktivierende Potenz der Pyrmidinderivate 
ATP und ADP näher untersuchen. Es war seit längerem bekannt, dass 
entsprechende Rezeptoren auf DC vorhanden waren. Die genaue Reaktion von 
DC nach Ligation dieser Rezeptoren war jedoch unklar. Wir konnten zeigen, 
dass extrazelluläres ATP einen synergistischen Effekt auf die Stimulation von 
DC hat. ATP ist ein strikt intrazelluläres Molekül und ein Auftauchen im 
extrazellulären Raum wird von DC registriert und mit einer Immunreaktion 
beantwortet. ATP erhöhte dabei transient die endozytotische Aktivität sowie die 
IL-12 Sekretion und T-Zell stimulierende Kapazität von DC. Dieser Effekt war in 
Kombination mit TNF-alpha stärker ausgeprägt. Zusätzlich konnte durch 
Blockung mit einem spezifischen Pyrimidinrezeptor-Antagonisten eine 
Rezeptorspezifität nachweisen werden.  
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Reproduktionsimmunologie 
Scholz C, Toth B, Brunnhuber R, Rampf E, Weissenbacher T, Santoso L, Friese 
K, Jeschke U. 
Glycodelin A induces a tolerognic phenotype in monocyte-derived dendritic 
cells in vitro. 
Am J Reprod Immunol. 2008 Dec;60(6):501-12.  
 
Im Gegensatz zu ATP verändern DC ihren Phänotyp bei einer Interaktion mit 
schwangerschafts-assoziiertem Glycodelin (Gd) in gänzlich anderer Weise. 
Dieses Protein musste zunächst aus Amnionflüssigkeit mittels High-
performance liquid chromatography (HPLC) gereinigt werden, da die 
spezifische Zuckerstruktur dieses Glykoproteins zu seiner Wirkung 
entscheidend beiträgt und es daher nicht rekombinant hergestellt werden kann. 
In nachfolgenden Experimenten mit humanen monozytenabgeleiteten DC zeigte 
sich ein charakteristisches Muster reifungsassoziierter Moleküle. CD83 und 
CD86  - zwei Moleküle, die eine Ausreifung anzeigen - waren bei der Inkubation 
mit Gd nicht erhöht, obwohl nachfolgend mit TNF-alpha versucht wurde eine 
Reifung herbeizuführen. Insgesamt zeigte sich bei diesen Experimenten ein 
Phänotyp, der am ehesten eine tolerogne Potenz vermuten ließ24. In der Tat 
waren funktionelle Assays, nämlich die T-Zell stimulierende Potenz sowie die 
Zytotoxizität DC-stimulierter Lymphozyten immer dann abgeschwächt, wenn DC 
mit Gd präinkubiert waren. Gd war dabei im experimentellen Ansatz lediglich 
am Beginn des Reifungsprozesses vorhanden. Der tolerogene Effekt auf DC war 
jedoch auch ohne aktuelle Gd-Exposition stabil.  Ein direkter Nachweis einer 
Rezeptorvermittlung dieses Effekts gelang uns allerdings experimentell nicht. 
Interessanterweise war in unseren Experimenten der C-type Lectin Rezeptor 
DC-SIGN in jenen Ansätzen signifikant erhöht, in denen DC mit Gd präinkubiert 
waren. Arbeiten, die eine Analyse der spezifischen Affinität dieses Rezeptors 
durchgeführt hatten, waren jedoch zu dem Ergebnis gekommen, dass die 
Zuckerstruktur eines fucosylierten Lac-di-NAc-N-Glycans die höchste 
Bindungsaffinität aufwies26. Diese Zuckerstruktur exisitert beim Menschen - 
soweit bislang bekannt - ausschließlich auf Gd. Ansonsten findet sich diese 
spezifische Verzuckerung beim Helminten insbesondere beim Pärchenegel 
Schistosoma mansoni27. Die hohe IL-10 Sekretion – ein Zytokin, das 
typischerweise bei Wurmerkrankungen erhöht ist - durch DC nach Inkubation 
mit Gd legt eine Verbindung zwischen dem immunolgischen Milieu der Plazenta 
und der Immunantwort einer parasitären Erkrankung mit Schistosomen nahe.  
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Toth B, Roth K, Kunert-Keil C, Scholz  C, Schulze S, Mylonas I, Friese K, 
Jeschke U.  
Glycodelin protein and mRNA is downregulated in human first trimester 
abortion and partially upregulated in mole pregnancy.  
J Histochem Cytochem. 2008 May;56(5):477-85.  
 
Wenn Gd, das immunogne Verhalten von DC so deutlich ändert und auch auf 
anderen Zellen des dezidualen Immunmilieus – insbesondere bei uNK Zellen – 
eine Wirkung entfaltet, so stellt sich die Frage, ob bei einer gestörter 
Plazentation eine Veränderung der Gd-Konzentration zu verzeichnen ist. Daher 
wurde Gewebe aus der normalen und gestörten Früh-Schwangerschaft (Abort 
und Molenschwagerschaft auf die Expression von Gd untersucht. Im Fall eines 
Abortes konnte eine erniedrigte Konzentration von Gd im Fall einer Molen-
Schwangerschaft eine erhöhte Konzentration nachgewiesen werden. Anhand 
von in vitro Experimenten konnten wir zusätzlich eine Vermittlung über den 
Gonadotropinrezeptor und eine Abhängigkeit von der βHCG-Konzentration 
nachweisen. 
 
Scholz C, Toth B, Santoso L, Kuhn C, Franz M, Mayr D, Jeschke U, Friese K, 
Schiessl B.  
Distribution and maturity of dendritic cells in diseases of insufficient 
placentation.  
Am J Rep Immunol 2008; 60:238–245. 
 
Frühaborte, also das Absterben der Schwangerschaft im ersten Trimenon, sind 
(abhängig vom maternalen Alter) in der überwiegenden Mehrzahl der Fälle 
genetisch bedingt. So kann eine Veränderung des Plazentamilieus immer auch 
als Epiphänomen gesehen werden. Im Gegensatz dazu sind die hypertensiven 
Schwangerschaftserkrankungen, die in der Spätphase der Schwangerschaft 
auftreten, Ausdruck einer bereits in der Frühschwangerschaft fehlgesteuerten 
Plazentation. Dabei unterbleibt als zentraler pathophysiolgischer Mechanismus 
der Umbau der Spiralarterien von einem Hochdrucksystem hin zu einem 
Niederdrucksystem mit venösen Charakteristika und einem Mitteldruck im 
intervillösen Raum am Ende der Schwangerschaft von ~10 mmHg. Dieser 
Umbau wird erzielt durch das Ersetzen der Muscularis durch Trophoblastzellen, 
bei dem uNK Zellen eine zentrale Rolle spielen. Dieser Ersatz kann nur im 
physiologischen immunologischen Milieu stattfinden, deren Teil das 
Trophoblastensystem ist. So verwundert es nicht, dass der Reifegrad von DC 
und die Verteilung innerhalb der Dezidua im Rahmen von hypertensiven 
Schwangerschaftserkrankungen verändert sind. Im Rahmen hypertensiver 
Schwangerschaftserkrankungen gelang es uns als erste Arbeitsgruppe, eine 
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Rolle des Aktivierungszustandes dendritischer Zellen am Patientenmaterial zu 
zeigen. DC zeigen dabei einerseits eine höhere Dichte jenes Rezeptors DC-
SIGN, wie wir es bereits bei in vitro Experimenten mit Gd gesehen hatten. Auf 
der anderen Seite konnten nachweisen werden, dass DC bei hypertensiven 
Schwangerschaftserkrankungen mit uNK Zellen co-lokalisieren und zusätzlich 
VEGF-R 1 und 2 überexpimieren. Wir konnten damit zum ersten Mal eine 
Verbindung zwischen plazentaren DC und den (fehlgesteuerten) 
Vaskularisationsprozessen der Plazenta zeigen.  
Tumorimmunologie 
Schnurr M, Galambos P, Scholz C, Then F, Dauer M, Endres S, Eigler A.  
Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against 
pancreatic carcinoma cells: an in vitro model for the assessment of tumor 
vaccines.  
Cancer Res. 2001; 61:6445-6450. 
 
DC als zentrale Steuereinheiten des adaptiven Immunsystems waren seit ihrer 
Entdeckung durch R. Steinman 1973 als Träger einer tumorgerichteten 
Immunantwort in der Diskussion23. Viele Studien wurden zwischenzeitlich an 
Patienten durchgeführt, ohne dass bislang eine routinemäßige klinische 
Anwendung außerhalb klinischer Studien erkennbar wäre. Auf der Suche nach 
in vitro Testsystemen konnten wir für die Anwendung mit Lysat von 
Tumorzellen ein diesbezügliches System etablieren. Über eine Dauer von 6 
Wochen wurden autologe T-Zellen mit antigenbeladenen DC so stimuliert, dass 
sich mit ihnen eine Anti-Tumor-Immunantwort in vitro generieren ließ. Mit 
diesem Testsystem war es nun möglich, Determinanten einer DC-gestützten 
Immuntherapie, z.B. Fragen des optimalen Reifestimulus oder der 
Antigenbeladung systematisch anzugehen.  
 
 
Schnurr M, Scholz  C, Rothenfusser S, Galambos P, Dauer M, Robe J, Endres S, 
Eigler A.  
Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-
priming of cytotoxic T cells and activate NK and gammadelta T cells.  
Cancer Res. 2002; 62:2347-2352. 
 
Die Art und Weise, wie eine DC Antigen aufnimmt, determiniert die daraus 
folgende Immunantwort. Für eine tumorgerichtete Immunantwort ist dabei eine 
von zytotoxischen T-Zellen (CTL) getragene Immunantwort sehr vorteilhaft. DC 
sind die einzigen Zellen des Immunsystems, die eine solche CTL-Immunantwort 
de novo generieren können. Ihre Eigenschaft der spezifischen Immuninduktion 
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prädestinieren DC für eine individualisierte Krebs-Immuntherapie. Deren 
immunogene Eigenschaften konnten wir in Zellkultur-Modellen beurteilen. 
Apoptose, als der physiologische Zelluntergang, induziert peripher (d.h. 
außerhalb lymphatischer Organe), vermittelt über DC, immunologische 
Toleranz. Apoptotisch zu Grunde gegangene Zellen werden dabei von DC 
aufgenommen und so aufbereitet, dass ihre charakteristische Proteinstruktur 
von CTL erkannt wird. Zusätzliche Signale bestimmen nun, ob diesen T-Zellen 
angezeigt wird, die betreffende Proteinstruktur zu tolerieren oder dagegen eine 
Immunantwort zu induzieren. Eine solche Immunantwort ist hochspezifisch und 
bietet sich daher als „targeted therapy“ in der Krebstherapie an. Wir konnten in 
diesem Zusammenhang den Weg apoptotischen Tumormaterials in Zellkultur-
DC genauer verfolgen und als Einflussfaktor der folgenden Immunantwort näher 
charakterisieren.  
Die Generierung einer solchen CTL-Immunantwort durch phagozytierte 
Antigene wird als cross-priming bezeichnet. Wir konnten zeigen, dass für 
apoptotische Antigene ein solches cross-priming stattfindet, wohingegen dies 
für nekrotisch zugrunde gegangenes Material nicht der Fall ist.  
 
Scholz C, Toth B, Barthell E, Mylonas I, Weissenbacher T, Friese K, Jeschke U. 
Immunohistochemical expression of glycodelin in breast cancer correlates with 
estrogen-receptor alpha and progesterone-receptor A positivity. 
Histol Histopathol. 2009 Apr;24(4):467-71. 
 
Jeschke U, Mylonas I, Kunert-Keil C, Stahn R, Scholz  C, Janni W, Kuhn C, 
Schröder E, Mayr D, Friese K. 
Immunohistochemistry, glycosylation and immunosuppression of glycodelin in 
human ovarian cancer. 
Histochem Cell Biol. 2009 Feb;131(2):283-95. 
 
Scholz C, Rampf E, Toth B, Brunnhuber R, Weissenbacher T, Friese K, Jeschke 
U 
Ovarian Cancer-derived Glycodelin Impairs In Vitro Dendritic Cell Maturation 
J Immunother. 2009 Jun;32(5):492-7. 
 
 
In einer weiteren Serie von Experimenten versuchten wir, den Einfluss des 
bereits an der fetomaternalen Grenzzone charakterisierten Gd auf die 
Pathophysiologie maligner gynäkologischer Erkrankungen zu beschrieben. 
Interessanterweise spielt Gd sowohl beim Mamma-Karzinom aber v.a. auch 
beim Ovarial-Karzinom eine Rolle. Beim Brustkrebs scheint dies insbesondere 
bei jenen histologischen Typen der Fall zu sein, bei denen noch ein gewisser 
Grad an Differenzierung vorhanden ist. Es kommt zu einer Korrelation zwischen 
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der Expression von Hormonrezeptoren und der vermehrten Sekretion von Gd. 
Erste funktionelle Daten konnten wir mit aus malignem Aszites gewonnenem Gd 
generieren. Zunächst wiesen wir eine differenzierte Glykosilierung von Ovarial-
Karzinom-Aszites-Gd vs. Amnionflüssigkeit-Gd nach. Die Glykosilierung hat 
ihrerseits einen entscheidenden Einfluss auf das Färbeverhalten in der 
Immunhistochemie aber v.a. auch auf die Rezeptorbindung z.B. an Muster-
Erkennungs-Rezeporen wie DC-SIGN. Auch das different glykosilierte 
Ovarialkarzinom-Gd zeigte einen deutlichen Effekt auf DC. Auch hier zeigt sich 
ein tolerogener Phänotyp, der hier nun – so unsere Interpretation - den maligne 
entarteten Zellen hilft ihr immunogenes Milieu zu formen. Hier scheint 
tatsächlich eine Nutzung im Rahmen der Plazentation erprobter Mechanismen 
im Kontext malignen Wachstums stattzufinden.  
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Krankheitsbilder 
Scholz C, Hermann C, Toth B, Kachler A, Kainer F, Friese K, Makrigiannakis 
A, Jeschke U 
Association of placental inflammation with fetomaternal hemorrhage and loss of 
placental mucin-1 
Eingereicht bei Gynecologic and Obstetric Investigation 
 
Scholz C, Kachler A, Hermann C, Weissenbacher T, Toth B, Friese K, Kainer F. 
Flowcytometric assessment of fetomaternal hemorrhage during external 
cephalic version at term. 
J Perinat Med. 2009;37(4):334-7. 
 
Eine der zentralen Aufgaben der fetomaternalen Grenzfläche ist die Trennung 
des mütterlichen und kindlichen Blutkreislaufes. Bei einem Leck dieser 
Trennung kann es zum Ausbluten des Feten in den Kreislauf der Mutter 
kommen. Mechanische Belastung wurde lange Zeit als ein Hauptriskofaktor für 
dieses seltene, jedoch in seinem Verlauf oftmals sehr dramatische 
Krankheitsbild gesehen. In einer Beobachtungsstudie konnten wir mit einem 
sehr sensitiven durchflußzytometrischen Testverfahren jedoch eine plazentare 
Entzündungsreaktion als bislang nicht beschriebenen Risikofaktor etablieren. 
 
Ein lange Zeit mit besonderer Aufmerksamkeit verfolgter Risikofaktor der 
fetomaternalen Transfusion war die mechanische Belastung im Rahmen der 
sog. äußeren Wendung, bei der ein Kind am Ende der Schwangerschaft aus 
Beckenendlage durch Manipulation von außen in eine Schädellage gedreht 
wird, um eine vaginale Geburt aus Schädellage zu ermöglichen. Die Sicherheit 
des Kindes steht dabei naturgemäß an oberster Stelle. Ebenfalls in einer 
klinischen Beobachtungs-Studie konnten wir mit o.g. Testverfahren dazu 
beitragen die Volumina der fetomaternalen Transfusion im Rahmen einer 
äußeren Wendung mit genauer zu quantifizieren und den Einfluss der 
mechanischen Belastung auf die fetomaternale Transfusion damit zu relativieren 
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Ausblick 
Derzeitig laufende Projekte beschäftigen sich mit der lokalen Immunreaktion 
des epithelialen Ovarialkarzinoms. Neueste noch unveröffentlichte Daten zeigen, 
dass in einer multivariaten Analyse die Sekretion von Gd bei Patientinnen mit 
einer epithelialen ovariellen Neoplasie pT3c signifikant mit dem 
Gesamtüberleben korreliert. Ebenso untersucht wird die Regulation des 
Chemokins CCL22, von dem durch Curiel et al. ebenfalls gezeigt werden konnte, 
dass seine Expression mit dem Gesamtüberleben von 
Ovarialkarzinompatientinnen korreliert6. Die zuletzt genannten Experimente 
werden in Fortführung der Kooperation der Frauenklinik mit der Abteilung für 
Klinische Pharmakologie der LMU durchgeführt.  
 
L Santoso, C Kuhn, S Kunze, K Friese, U Jeschke, C Scholz 
TLR2-ligation Listeria moncytogenes and its effects on the cytokine profile 
of trophoblast cells 
Manuskript in Vorbereitung 
 
Reproduktionsimmunologisch beschäftigen wir uns derzeit mit der 
trophoblastären Reaktion auf Liganden für Mustererkennungsrezeptoren. 
Gerade abgeschlossene Experimente zeigen eine differenzierte Expression und 
Reaktion des ST und ZT auf eine TLR-2 Ligation mit Listeria moncytogenes. 
Interessanterweise führt eine Ligation von TLR-2 beim Trophoblast zu keiner 
angepassten Immunantwort, sonder fördert eher die Vermehrung von L. 
moncytogenes. Dies könnte dazu beitragen, das Phänomen des 
Plazentatropismus von L. monocytogenes zu erklären. Während diese 
Erkrankung außerhalb der Schwangerschaft in der Regel sehr harmlos verläuft, 
kommt es in der Schwangerschaft zu einer selektiven Vermehrung der Listerien 
in der Plazenta2. Erst dieser immunologisch sichere Hafen macht die 
Erkrankung in der Schwangerschaft zu einer Gefahr für die Mutter aber 
insbesondere auch für das Kind.  
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Abkürzungsverzeichnis 
ATP  Adenosin-5´triphosphat 
ADP  Adenosin-5´diphosphat 
CD  Cluster of differentiation 
CD(x)+  Positiv für einen Oberflächenmolekül x 
CTL  zytotoxische T Zelle 
DC  Dendritische Zelle 
ELISA  Enzyme-linked immunosorbent assay 
FACS  Fluorescence-activated cell sorter 
Gd  Glycodelin 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
HLA  Humanes Leukozyten-Antigen 
IU  Internationale Einheit 
IL  Interleukin 
MHC  Major histocompatibility complex 
min    Minute 
O2  Sauerstoff 
ST  Syzytiotrophoblast  
TLR  Toll-Like Rezeptor 
TNF-alpha Tumornekrosefaktor-α 
uNK Zelle uterine natürliche Killerzelle 
VEGF  vacular endothelial growth factor 
ZT  Zytotrophoblast 
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Cross-Priming of Cytotoxic T Cells and Activate NK and !" T Cells1
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ABSTRACT
Tumor vaccines using dendritic cells (DCs) have been shown to induce
antitumor CTL responses. The choice of the tumor antigen preparation
used for DC loading is still an unresolved issue. We compared DCs pulsed
with cell lysates, whole apoptotic tumor cells or their supernatants of the
HLA-A2# human pancreatic carcinoma cell line Panc-1 for their capacity
to activate T cells. Monocyte-derived DCs from HLA-A2# donors were
pulsed with tumor antigen, matured subsequently, and cocultured with
autologeous peripheral blood mononuclear cells. After three weekly re-
stimulations with DCs, T-cell activation was assessed by intracellular
IFN-! staining and cytotoxicity assays. Compared with lysate, pulsing
DCs with the supernatant of apoptotic tumor cells induced a higher
frequency of activated CTLs and T-helper cells, as well as an enhanced
MHC class I-restricted tumor cell lysis. No activation of natural killer
(NK) or !" T cells was detected. Pulsing DCs with whole apoptotic tumor
cells induced an even more pronounced lytic effect. However, in this case,
MHC class-I blocking was only partially effective, and unrelated cell lines
were also killed. IFN-! staining revealed activation of CTLs and T-helper
cells, as well as NK and !" T cells. Trans-well cultures of NK cells,
apoptotic tumor cells, and DCs showed that NK cell activation was
dependent on direct cell-to-cell contact with tumor cells and the presence
of interleukin-12 produced by DCs. These results indicate that the choice
of antigen preparation is a critical determinant in the induction of anti-
tumor immunity. Tumor vaccines consisting of DCs and apoptotic tumor
cells may be able to activate CTLs, as well as effector cells of the innate
immune system.
INTRODUCTION
Tumor vaccines aim at inducing CTL responses against tumor
antigens to mount an immune response against tumors. The activation
of CTL requires presentation of the antigen in the context of MHC
molecules on the surface of antigen-presenting cells. DCs4 are the
most effective antigen-presenting cells (1), and tumor vaccinations
with DCs have been shown to induce CTL responses and tumor
regression in some patients (2–6). In contrast to CTL, NK cells and !"
T cells, effector cells of the innate immune system, have the capacity
to recognize and kill tumor cells in an antigen-independent manner.
There is evidence that DC can link innate and acquired effector
mechanisms (1) either by direct cell-to-cell contacts (7) or by secret-
ing cytokines (8, 9). Activation of effector cells of the innate immune
system by DC might be a prerequisite for antitumor immunity in
MHC class-I-negative tumors (7) and, under certain circumstances,
for successful CTL responses (10).
Compared with tumors, such as renal cell carcinoma and malignant
melanoma, pancreatic carcinoma is considered to be weakly immu-
nogenic. In addition, pancreatic cancer cells exhibit several mecha-
nisms of immune evasion, such as the expression of the apoptosis-
inducing molecule Fas-ligand (11), defective signaling via Fas (12),
and secretion of transforming growth factor-#, a growth factor known
to interfere with DC function (13). Nevertheless, as we have shown
previously, CTL responses against pancreatic cancer cells can
be induced in vitro using DCs (14). Therefore, vaccination with
DCs might offer a therapeutic option for patients with pancreatic
carcinoma.
A critical issue in optimizing DC vaccines is the choice of tumor
antigen for DC loading. Clinical vaccination trials for patients with
malignant melanoma have demonstrated that vaccinating against a
single antigen can induce tumor-specific CTLs but carries the risk of
promoting tumor antigen escape variants (6). A more recent trial
showed that the generation of CTLs against three or more tumor
antigens correlates with clinical response (15). However, for many
tumors, no or only few antigenic epitopes are known. To circumvent
this limitation, whole tumor cells containing a spectrum of known, as
well as yet unknown antigens, might be used as an antigen source. The
additional presence of epitopes for T-helper lymphocytes could be
beneficial because MHC II-restricted activation of T-helper lympho-
cytes plays a pivotal role in the physiological immune response to
pathogens and might be of considerable importance in the process of
tumor rejection (16).
Effective cross-priming with antigens from tumor cells has been
demonstrated with tumor cell lysates (17), apoptotic tumor cells
(18–22), and released particles from tumor cells, such as apoptotic
bodies (23) and tumor-derived exosomes (24, 25). In the present
study, we compared DCs pulsed with cell lysates, apoptotic cells, or
released particles from apoptotic cells obtained from pancreatic car-
cinoma cells for their ability to cross-prime CTLs, as well as to
activate T-helper and effector cells of the innate immune system.
MATERIALS AND METHODS
Media and Reagents. RPMI 1640 (Biochrom, Berlin, Germany) supple-
mented with 2% human serum (BioWhittaker, Walkersville, MD), 2 mM
L-glutamine (Life Technologies, Inc., Paisley, Scotland), 50 units/ml penicil-
lin, and 50 $g/ml streptomycin (Sigma Chemical Co., Munich, Germany) was
used to culture cells from PBMCs. Recombinant human cytokines: granulocyte
macrophage colony-stimulating factor was purchased from Novartis (Basel,
Switzerland), IL-4 from Promega (Madison, WI), IL-2 and IL-7 from Strath-
man Biotech (Hanover, Germany), and TNF-% from R&D Systems (Wiesba-
den, Germany). Prostaglandin E2, CFSE, fluorochrome-labeled PKH-26, PI,
and brefeldin A were obtained from Sigma Chemical Co. [3H]thymidine was
purchased from Amersham Buchler (Freiburg, Germany) and Na2[51Cr]O4
from NEN Life Sciences (Zavantem, Belgium).
Isolation and Culture of Cells. PBMCs were obtained from peripheral
blood or buffy coats of healthy HLA-A2! blood donors by Ficoll-Hypaque
density gradient centrifugation. Monocyte-derived DCs were generated from
the adherent fraction of PBMCs cultured in the presence of granulocyte
macrophage colony-stimulating factor (1000 units/ml) and IL-4 (500 units/ml)
for 6 days as described (14). NK cells were enriched from PBMCs by
magnetically activated cell sorting using the isolation kit for untouched NK
Received 12/6/01; accepted 2/7/02.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance with
18 U.S.C. Section 1734 solely to indicate this fact.
1 This work is part of the thesis of C. Scholz at the Ludwig-Maximilians-University,
Munich, Germany. M. Schnurr is supported by a grant from the university of Munich
Fo¨FoLe No. 216.
2 M. S. and C. S. contributed equally to this manuscript.
3 To whom requests for reprints should be addressed, at Medizinische Klinik Innen-
stadt, Ziemssenstr. 1, 80336 Munich, Germany. Phone. 49-89-51602378; Fax: 49-89-
51604406; E-mail: Andreas.Eigler@med.uni-muenchen.de.
4 The abbreviations used are: DC, dendritic cell; NK, natural killer; PBMC, peripheral
blood mononuclear cell; TNF, tumor necrosis factor; IL, interleukin; PI, propidium iodide;
CFSE, carboxy-fluorescein diacetate succinimidyl ester; mAb, monoclonal antibody;
PGE2, prostaglandin E2; hsp, heat shock protein.
2347
cells from Miltenyi Biotec (Bergisch Gladbach, Germany) according to the
manufacturer’s protocol. The purity of isolated CD3" CD56! NK cells was
#95%. The human pancreatic carcinoma cell line Panc-1 (HLA-A2!) and the
NK cell-sensitive cell line K562 were purchased from European Collection of
Animal Cell Cultures (Salisbury, Great Britain); the gastric carcinoma cell line
Kato-III (HLA-A2!) was obtained from American Type Culture Collection.
Tumor cells were maintained in RPMI 1640 supplemented with 10% FCS
(Biochrom), L-glutamine, penicillin, and streptomycin.
Preparation of Tumor Antigens. Tumor antigens were obtained from
Panc-1 tumor cells. Tumor cell lysates were generated by three rapid freeze-
thaw cycles as described (14). To induce tumor cell apoptosis, 3 $ 106 tumor
cells were suspended in medium and exposed to 150 mJ/cm2 UV-B light or
43°C for 2 h. Subsequently, cells were cultured at 37°C on a shaker (30 rpm)
to prevent cells from adhering to the culture dish. After 24–32 h, most tumor
cells were early apoptotic, defined as annexin V positive and PI negative. By
48–72 h, all tumor cells had died staining positive for annexin V and PI. In our
experiments, tumor cells were separated from their supernatant by centrifuga-
tion (10 min at 300 $ g) after 24–32 h to obtain two fractions consisting of
apoptotic tumor cells and low-density fragments, such as apoptotic bodies and
other released tumor constituents.
Detection of Apoptosis. To detect apoptosis after heat or UV-B exposure,
2 $ 106 tumor cells were stained with FITC-conjugated annexin V (Bender
Med Systems, Vienna, Austria), and 1 $g/ml PI was added shortly before
analysis by flow cytometry.
Tumor Antigen Uptake by DCs. Panc-1 tumor cells were stained with
CFSE (1 $M) and DCs with PKH-26-FITC (2 $M) according to the manufac-
turer’s protocols. Tumor cells were exposed subsequently to UV-B light or
43°C. After 24 h, equal numbers of tumor cells (or their supernatants) were
incubated with DCs. Phagocytosis was assessed at various time points by flow
cytometry and fluorescence microscopy in two-well chamber slides (Nunc,
Wiesbaden, Germany). Intracellular uptake of tumor cell particles was con-
firmed by confocal laser microscopy (LSM 410 Invert; Carl Zeiss, Jena,
Germany). Digital images were obtained in 10 focal planes separated by 1 $m
and processed with PhotoShop 3.0 (Adobe Systems, San Jose, CA).
Coculture of DCs with Autologeous PBMCs. DCs were pulsed with
tumor cell lysate, apoptotic tumor cells, or their supernatants (one tumor cell
equivalent per DC) for 4 h, extensively washed, and incubated with TNF-%
(1000 units/ml) and PGE2 (1 $g/ml) for 24 h to induce a mature phenotype
(26). These DCs were cocultured with autologeous nonadherent PBMCs at a
ratio of 1:20. Every 7 days, the cultures were restimulated with new DCs.
One-third of the medium was replaced on days 3, 5, and at each restimulation
by fresh culture medium containing IL-2 (25 units/ml) and IL-7 (10 ng/ml).
Flow Cytometry. Surface antigen staining was performed as described
previously (14). Fluorescence-labeled mAb against CD4, CD8, CD14, CD56,
CD69, CD80, CD83, CD86, and HLA-DR was purchased from PharMingen
(San Diego, CA), anti-CD3-PerCP from Becton Dickinson (San Jose, CA), and
anti-V!9-FITC from Coulter Immunotech (Marseilles, France). For the detec-
tion of intracellular IFN-!, cells were incubated with brefeldin A (1 $g/ml)
during the last 4 h before harvest. Cells were stained with mAb against the
surface markers of interest (CD3, CD4, CD8, or CD3, V!9, and CD56), fixed,
permeabilized, and stained with anti-IFN-!-phycoerythrin (Becton Dickinson).
Quantitation of Cytokine Secretion. Supernatants of the cocultures were
harvested, and concentrations of human cytokines IL-12 (p40/p70; Bender
Med Systems), IFN-!, IL-10, and IL-4 were quantified by ELISA (Becton
Dickinson) as duplicates.
Cytotoxicity Assay and MHC Class-I Blocking. After four weekly stim-
ulations with DCs, the lytic activity of PBMCs was assessed in a 51Cr-release
assay. A suspension of single target cells was incubated with 100 $Ci
Na2[51Cr]O4/106 cells for 1 h and washed five times. Tumor cells, 5 $ 103/
well, were incubated with PBMCs from the cocultures at E:T ratios ranging
from 80:1 to 10:1 in round-bottomed, 96-well microtiter plates. Optimal
incubation periods were determined for each target cell line by aiming for a
low (experimental counts/spontaneous counts) ratio. The incubation period
was 16 h for Panc-1 and Kato-III and 4 h for K562. Thereafter, 100 $l of
supernatant of each well were collected, and radioactivity was measured with
a gamma counter (Wallac Oy, Turku, Finland). Specific lysis was calculated by
the formula: specific 51Cr-release % [(experimental counts " spontaneous
counts)/(maximal counts " spontaneous counts) $ 100%]. Where indicated,
MHC class I molecules of the target cells were blocked with 10 $g/106 cells
of the mAb W6/32 (Serotec, Oxford, United Kingdom).
Trans-well Cultures of DCs, Apoptotic Tumor Cells, and NK Cells.
Tissue culture inserts with a pore size of 0.3 $m (Nunc) were used to create
two compartments within culture plates to separate NK cells, DCs, or apoptotic
Panc-1 tumor cells from the other cell types. Anti-IL-12 p40/p70 (clone C11.5,
30 $g/ml) and anti-IL-15 (clone 34505.11, 50 $g/ml) mAb (R&D Systems)
were used as indicated. After 48 h, NK cell activation was assessed by
intracellular IFN-! staining as described above.
Statistical Analysis. Data are expressed as means & SE. Statistical signif-
icance was determined by the Student t test for paired samples of original
values. Differences were considered statistically significant for P ' 0.05.
RESULTS
DCs Internalize Constituents of Apoptotic Tumor Cells. Apo-
ptosis of Panc-1 tumor cells was induced by UV-B light or hyper-
thermia as assessed by annexin V and PI staining (Fig. 1A). After
24–48 h, when most tumor cells were early apoptotic (annexin V
positive and PI negative), apoptotic tumor cells and their supernatants
were separated and used for additional experiments. To study uptake
of apoptotic tumor cells or released particles by immature DCs, tumor
cells were stained with CFSE before the induction of apoptosis.
PHK-26-PE-stained DCs were incubated with apoptotic tumor cells or
their supernatants and analyzed by flow cytometry. Supernatant-
pulsed DCs showed an increase of fluorescence intensity in the CFSE
channel, indicating uptake of tumor-derived particles (Fig. 1B, left
graph). To determine the capacity of DCs to capture whole apoptotic
tumor cells, DCs were mixed with tumor cells in equal numbers.
Double-positive cells represented DCs engulfing tumor cells (Fig. 1B,
right graph). Intracellular uptake of tumor cells was confirmed by
fluorescence and confocal microscopy (Fig. 1C). Neither apoptotic
tumor cells nor their supernatants were toxic to DCs or induced
maturation as assessed by PI staining and the lack of CD83 expres-
sion, respectively (data not shown).
Antigen-loaded DCs Induce a Th1 Cytokine Profile in Cocul-
tures with PBMCs. Immature DCs were pulsed with lysate, apo-
ptotic tumor cells, or their supernatants and were matured in the
presence of TNF-% and PGE2. After 24 h, the DCs expressed high
levels of costimulatory molecules and the maturation marker CD83.
These DCs were cocultured subsequently with autologeous PBMCs at
a ratio of 1:20 in the presence of low doses of IL-2 and IL-7, and new
DCs were added every 7 days. IFN-! was detected in increasing
concentrations after each stimulation in the culture medium of cocul-
tures of PBMCs with antigen-pulsed DCs but not in the cultures with
unpulsed DCs or PBMCs without DCs. When the different antigen
preparations were compared, the highest amount of IFN-! was found
when apoptotic tumor cells were used as the source of antigen with no
significant difference between UV-B- and hyperthermia-induced apo-
ptosis (Fig. 2). The supernatant of apoptotic tumor cells induced less
IFN-! but significantly more than tumor lysate (P ' 0.01 for heat-
and P % 0.02 for UV-B-induced apoptosis). IL-4 and IL-10 were
below the detection limit under any of these culture conditions (data
not shown).
DCs Loaded with Tumor Antigens Elicit CTLs Able to Kill
Pancreatic Carcinoma Cells. After four stimulations with DCs, the
PBMCs were tested for their lytic activity against Panc-1 tumor cells
in a 51Cr-release assay. The lytic activity correlated with the amount
of IFN-! found in the culture medium, the highest tumor lysis being
detected when apoptotic tumor cells were used for DC pulsing fol-
lowed by supernatant and lysate (Fig. 3). Again, no statistical differ-
ence could be seen between UV-B- and heat-treated tumor cells.
Supernatant of apoptotic tumor cells induced higher cell lysis rates
than lysate. The difference was statistically significant for hyper-
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thermia-induced apoptosis (P ' 0.01) but not for UV-B-induced
apoptosis (P% 0.09). To determine the involvement of tumor antigen-
specific CTLs in tumor killing, the experiments were also performed
in the presence of the MHC class I-blocking antibody W6/32. Tumor
cell lysis was effectively blocked in the experiments with antigens
from cell lysate or tumor cell supernatant indicative of CTL-mediated
tumor cell killing (Fig. 3). If CTL-mediated killing was defined as the
difference between lysis without and with MHC I blocking, apoptotic
tumor cell supernatants as antigen source were significantly superior
to lysate (P ' 0.01). Interestingly, PBMCs of the cocultures with
apoptotic tumor cell-pulsed DCs still effectively killed tumor cells
after MHC I blocking. Moreover, these cells were capable of lysing
the unrelated gastric carcinoma cell line Kato-III, as well as the NK
cell-sensitive cell line K562 (Fig. 4).
Apoptotic Tumor Cells Induce Activation of NK and !" T
Cells. To determine the activation pattern of different leukocyte sub-
sets from PBMCs in the cocultures, we analyzed IFN-! production of
Fig. 1. Immature DCs internalize apoptotic
Panc-1 tumor cells and released particles. Annexin
V-FITC and PI staining show apoptosis of tumor
cells after exposure to UV-B light (A). DCs capture
constituents of apoptotic tumor cells (B). CFSE-
stained apoptotic tumor cells (dotplots) or their
supernatants (histogram) were incubated with
PHK-26-stained DCs at a ratio of 1:1 for 4 h and
analyzed by flow cytometry. Controls were incu-
bated on ice. Internalization of tumor cells was
analyzed by fluorescence and confocal microscopy
(C). From left to right, a DC engulfs a tumor cell
fragment (green, top right) 30 min after coincuba-
tion. Three confocal plains confirm intracellular
position of a tumor cell fragment (green).
Fig. 2. IFN-! production by PBMCs cocultured with tumor antigen-loaded DCs. DCs
were pulsed with tumor lysate, supernatants of apoptotic tumor cells, or whole apoptotic
tumor cells. After maturation with TNF-% and PGE2, the DCs were cocultured with
autologeous nonadherent PBMCs. The graph shows concentrations of IFN-! in the
supernatants of the PBMCs after the fourth weekly stimulation with DCs (mean & SE,
n % 6).
Fig. 3. Tumor cell killing by PBMCs stimulated with tumor antigen-pulsed DCs. DCs
were pulsed with tumor cell lysate, supernatants of apoptotic tumor cells, or whole
apoptotic tumor cells. Subsequently, DCs were washed, activated with TNF-% and PGE2,
and cocultured with autologeous PBMCs. Two days after the fourth weekly stimulation
with DCs, the lytic activity of the PBMCs was assessed using 51Cr-labeled Panc-1 tumor
cells as targets in a 51Cr-release assay (solid bars). To determine MHC class I restriction
of tumor cell killing, the target cells were preincubated with the MHC class I-blocking
antibody W6/32 (open bars). The specific lysis at an E:T ratio of 80:1 is shown (mean &
SE, n % 6).
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CTLs (CD3! CD8!), T helper cells (CD3! CD4!), NK cells (CD3"
CD56!), and !" T cells (CD3! V!9!) by flow cytometry. As
expected from the cytotoxicity assays, the activation pattern of leu-
kocyte subsets was quite different if whole apoptotic tumor cells were
chosen as the source of antigen compared with supernatant or lysate
(Fig. 5). A portion (23% hyperthermia and 19% UV-B) of NK cells
were activated in PBMCs cocultured with apoptotic tumor cell-pulsed
DCs. Furthermore, 30% (hyperthermia) and 36% (UV-B) of !" T
cells stained positive for IFN-! under the same conditions. In contrast,
only a small number of NK and !" T cells from cocultures with
supernatant- or lysate-pulsed DCs produced IFN-!. No significant
differences in CTL activation could be seen between apoptotic tumor
cell-pulsed versus supernatant-pulsed DCs. However, both conditions
were clearly superior to lysate with a higher frequency of IFN-!-
producing CTLs and T-helper cells.
NK Cell Activation Is Dependent on Tumor Cell Contact and
IL-12 Produced by DCs. Because tumor cells, which were not
internalized by DCs, were still present in the cocultures of PBMCs
with tumor cell-pulsed DCs, we were interested if direct tumor cell
contact with NK cells was necessary for NK cell activation or if DC
directly triggered NK cell activation. Activation of NK cells (puri-
ty # 95%) was studied by intracellular IFN-! staining in a trans-well
culture system allowing only direct contact between two of the three
cell types: DCs and apoptotic tumor cells, NK cells and apoptotic
tumor cells, or DCs and NK cells. Only in cultures that allowed direct
cell-to-cell contact between NK cells and apoptotic tumor cells, NK
cell activation was observed (Fig. 6). However, no NK cell activation
was seen in the absence of DCs (data not shown). Therefore, most
likely, a soluble factor secreted by DCs was involved. Adding IL-12
was able to substitute for DCs. Moreover, IL-12-blocking antibodies
inhibited activation when DCs were present (Fig. 6), whereas block-
ing IL-15 showed no effect. This indicated that NK cell activation
depended on both direct cell contact with tumor cells, as well as
DC-derived IL-12.
DISCUSSION
Cross-priming of CTLs with antitumor activity has been demon-
strated with DCs pulsed with tumor cell lysates (17), apoptotic tumor
cells (18–22), and apoptotic bodies (23), but to our knowledge, no
quantitative comparison has been undertaken. In this study, we inves-
tigated the ability of monocyte-derived DCs pulsed with different
antigen preparations from the pancreatic carcinoma cell line Panc-1 to
induce an antitumor T-cell response in a cross-presentation in vitro
model. The antigen preparations consisted of: (a) tumor cell lysates;
(b) UV-B- or hyperthermia-induced apoptotic tumor cells; or (c) their
supernatants, containing low-density particles released from the cells,
such as apoptotic bodies. Immature DCs internalized tumor cells, as
well as released particles, as shown by flow cytometry and confocal
microscopy. After antigen loading, we activated the DCs with cyto-
kines to induce a T-cell stimulatory phenotype for effective T-cell
priming.
Our results showed that antigens from apoptotic tumor cells, whole
cells as well as released particles, were more potent than tumor lysates
in inducing T-cell priming and activation by DCs. This was evidenced
by enhanced IFN-! secretion and a higher frequency of activated
CTLs and T-helper cells, as well as a higher rate of MHC class
I-restricted tumor cell killing. This result is in agreement with a report
from Hoffman et al. (19), who observed stronger CTL responses with
apoptotic tumor cells, compared with cell lysates in a squamous cell
carcinoma model. Enhanced CTL activation by antigens from apo-
ptotic cells may be attributed to several mechanisms. After internal-
ization, most particulate antigens requiring phagocytosis are digested
into peptides associating with MHC class-II molecules in the endo-
cytic compartments and are presented to T-helper cells (27). This is
believed to be the predominant processing pathway of cell lysates. In
contrary, scavenger receptor-mediated phagocytosis of apoptotic tu-
mor cells allows antigens to gain access to MHC class-I compart-
ments, resulting in cross-presentation of the antigen to CTLs (18, 28).
In addition, enhanced CTL responses against tumors might be medi-
ated by hsps expressed by stress-induced apoptotic tumor cells (29).
Hsps have been shown to improve uptake of antigens by DCs (30) and
can provide additional antigenic epitopes by peptides complexed to
hsp (31). On the basis of this theoretical background and our own
observations, we conclude that antigen preparations from apoptotic
Fig. 4. PBMCs from cocultures with apoptotic tumor cell-pulsed DCs effectively kill
unrelated tumor cell lines. After four weekly stimulations of PBMCs with DCs pulsed
with different antigen preparations from Panc-1 tumor cells, the killing of the unrelated
HLA-A2! gastric carcinoma cell line Kato-III (n% 6) and the NK-sensitive cell line K562
(n % 5) was assessed in a 51Cr-release assay. The specific lysis at an E:T ratio of 80:1 is
shown (mean & SE).
Fig. 5. Activation pattern of different lymphocyte subsets in PBMCs cocultured with
tumor antigen-pulsed DCs. PBMCs were removed 12 h after the fourth stimulation with
DCs, and intracellular IFN-! was stained after incubation with brefeldin A. In a four-color
flow cytometric analysis, CTLs were identified as CD3! CD8!, T-helper cells as CD3!
CD4!, NK cells as CD3" CD56!, and !" T cells as CD3! v!9!. Data represent means
of percentage of IFN-!-positive cells & SE (n % 5).
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tumor cells represent a promising alternative to tumor lysate in DC-
based tumor vaccines.
Tumor cell killing was highest when whole apoptotic tumor cells
were used as the source of antigen. However, compared with exper-
iments with supernatant or lysate, tumor cell killing was only partially
MHC class I restricted. Moreover, unrelated cell lines were also
effectively killed. The analysis of the activation pattern of different
leukocyte subsets in these cocultures revealed not only activation of
CTLs and T-helper cells but also of NK cells and !" T cells. The latter
two are effector cell types of the innate arm of the immune defense
with the ability to kill tumor cells in an antigen-unspecific manner. In
a recent study, vaccinating mice with DC cocultured with tumor cells
induced CTL-mediated protective immunity, as well as NK cell acti-
vation (10). Interestingly, in that study, NK cell depletion abrogated
tumor protection favoring the concept that combining innate and
acquired effector mechanisms may enhance tumor immunogenicity.
Mechanisms leading to NK and !" T-cell activation by tumor cells
are only understood incompletely. Activation seems to be influenced
by a balance of negative and positive signals. A positive signal can be
mediated by the NKG2D-DAP10 receptor complex, expressed on the
surface of NK cells and !" T cells, which is known to interact with
stress-induced ligands on tumor cells, such as MICA and Rae-1
(32–35). Stimulation via NKG2D can override negative signals from
inhibitory receptors and triggers degranulation and perforin-mediated
apoptosis of the tumor cell. Another concept favors that direct cell-
to-cell contact between DCs and NK cells enhances the cytolytic
activity of NK cells (7). In our experiments, apoptotic tumor cells
were present in cocultures of PBMCs with apoptotic tumor cell-pulsed
DCs. This was not the case in the cocultures with supernatant- or
lysate-pulsed DCs, because excess antigen was removed by washing.
Therefore, it seemed likely that cell contacts of tumor cells with NK
cells within the PBMCs played a role in the observed NK cell
activation. When we analyzed the required components for this effect
in a trans-well cultures system, we found that direct cell contact
between NK cells and apoptotic tumor cells was required, as well as
a soluble factor produced by DCs. A recent report also points into this
direction, but the factor was not identified (36). In cytokine-blocking
experiments, we found that NK cell activation was dependent on
DC-derived IL-12. Therefore, DCs played a dual role in these cul-
tures: (a) they cross-presented tumor antigen to T cells inducing
tumor-specific CTLs; and (b) they activated innate effector cells via
IL-12. A vaccination trial using DCs fused with tumor cells, achieved
promising results in patients with renal cell carcinoma (4). Because in
that study fusion was only effective partially, unfused tumor cells
were injected together with DCs; possibly, activation of innate effec-
tor cells by direct contact with stressed tumor cells in the presence of
DC-derived IL-12 played a role in the vaccination success observed in
some patients.
In conclusion, pulsing DCs with antigen from apoptotic tumor cells
seems to be a promising alternative to lysate and might be used for
tumors when immunogenic epitopes are unknown. Furthermore, a
vaccine containing apoptotic tumor cells in addition to DCs could
offer advantages by stimulating effector cells of the innate immune
system. Activation of NK cells and !" T cells at the injection site
could provide stimuli for local antigen-presenting cells, enhancing the
effectiveness of the vaccine. However, the efficacy of this strategy
needs further evaluation.
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Introduction
Mammalian reproduction has to overcome unique
immunological challenges, as the semiallogeneic
blastocyst expresses alloantigens inherited from the
father. The growing fetus is not merely tolerated by
the maternal immune system during pregnancy.
There is growing evidence that the immunological
equilibrium at the feto-maternal interphase plays an
integral part during placentation.1 Hypertensive dis-
eases of pregnancy have been associated with
immune phenomena.2,3 The notion exists that that
trophoblast invasion is disturbed by a dysfunctional
maternal immune reaction, resulting in incomplete
spiral artery transformation with subsequent placen-
tal insufficiency and feto-maternal compromise.4
Dendritic cells (DC) have long been known to be
central regulators of adaptive immunity.5,6 Recent
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Problem
The immunological equilibrium at the feto-maternal interphase contrib-
utes towards late gestational diseases like growth restriction (IUGR) pre-
eclampsia (PE) and hemolysis, elevated liver enzymes, low platelets
(HELLP)-syndrome. The state of activation of decidual dendritic cells
(DC) has emerged as one of the central players influencing this immu-
nological equilibrium.
Method of study
Paraffin-embedded tissue sections from 27 pregnancies were immuno-
stained for DC markers DEC-205, DC-SIGN, DC-LAMP and costained for
DC-SIGN ⁄CD56 and DC-SIGN ⁄ vascular endothelial growth factor recep-
tor (VEGFR) -1 and -2. We investigated placental tissue of IUGR fetuses
and of patients who developed PE or HELLP-syndrome as well as pla-
cental tissue derived from normal pregnancies.
Results
We found that expression of DEC-205 and DC-SIGN was significantly
upregulated in HELLP placentas, whereas expression of DC-LAMP was
abrogated almost entirely. Costaining showed an interaction between
DC-SIGN+ DC and natural killer cells as well as costaining of VEGFR-1
and -2 and DC-SIGN. Pre-eclamptic and IUGR placentas showed no sig-
nificant change in any of the investigated markers compared to normal
controls.
Conclusion
Our data suggest a participation of DC-mediated immunological mecha-
nisms in HELLP syndrome.
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research, however, points toward a role of DC in
maintaining peripheral tolerance.7 Accumulating
data show that DC contribute significantly towards
mucosal tolerance to exogenous antigens in the skin,
lung, and gut.8–10 The concept of DC as the ‘gate-
keepers of mucosal immunity’ has recently been
extended to uterine mucosal immunity and its
immunological relationship to the semi-allogeneic
conceptus.11 The state of activation of DC determines
their immune-stimulatory capacities and therefore
might contribute toward optimal decidual immune
responses supporting placento-fetal development.12
In the reported experiments, we assessed
immune-histochemical maturation markers of decid-
ual DC in placental tissue of pregnancies complicated
by pre-eclampsia (PE) (de novo hypertension, and
proteinuria) beyond 20 weeks of gestation, HELLP-
syndrome (hemolysis, elevated liver enzymes, low
platelets) and intrauterine growth restriction (IUGR).
Materials and methods
Tissue Samples
Placental tissues were obtained from 27 women who
had given birth in the first Department of Obstetrics
and Gynaecology of the LMU Munich. Six placentas
with IUGR (mean date of delivery ± S.D.:
33 ± 3 weeks of gestation), eight placentas with PE
(mean date of delivery: 33 ± 3.2 weeks of gestation),
five placentas with HELLP (mean date of delivery:
33.8 ± 2.9 weeks of gestation) and eight normal pla-
centas (mean date of delivery: 38.2 ± 3 weeks of
gestation) were used for the study (see supplemen-
tary data Table S1 for fetal clinical outcome).
Fetal intrauterine growth restriction was defined
as an estimated intrauterine weight below the fifth
centile after gestational age had been confirmed by
an early pregnancy ultrasound. IUGR needed to be
confirmed after delivery; otherwise the patient was
excluded from the study.
Pre-eclampsia was defined as maternal hyperten-
sion >140 ⁄90 mmHg without previous hypertensive
history and 300 mg ⁄L proteinuria without any his-
tory of renal disease.
Patients with HELLP-syndrome included in the
study had a minimum of twofold increased liver
enzymes, platelets below 100,000 ⁄lL and detectable
haptoglobin below the normal range. The study was
approved by the ethics committee of the Faculty
of the Ludwig-Maximilians-University Munich,
Germany, and informed consent was obtained from
each patient.
Placental samples were taken at three central parts
of the placenta. Obtained tissue was frozen immedi-
ately after delivery and stored at )20C. A second
set of placental tissue was fixed immediately after
delivery in 4% buffered formalin for 20–24 hr and
embedded in paraffin afterwards.
Immunohistochemistry
All paraffin-embedded specimens were cut to 2–
3 lm and mounted on SuperFrost ⁄Plus microscope
slides (Menzel, Walldorf, Germany). After deparaff-
inization and rehydration, slides of different pla-
cental tissue specimens were incubated in
methanol ⁄H2O2 (30 min) to inhibit endogenous
peroxidase activity. This was followed by washing
in phosphate-buffered saline (PBS, pH 7.4) (5 min)
and treatment with rabbit or horse serum (20 min,
22C, Vector laboratories, Burlingame, CA, USA) to
reduce non-specific background staining. There was
no pre-treatment of the slides. Tissues were incu-
bated with the primary antibodies (see supplemen-
tary data Table S2) for 1 hr at room temperature.
Sections were incubated with the biotinylated sec-
ondary antibody (1 hr, 22C, Vector laboratories)
and avidin-biotinylated peroxidase (45 min, room
temperature, Vector laboratories). In between each
step, sections were washed with PBS. Peroxidase
staining reaction was performed with diam-
inobenzidine ⁄H2O2 (1 mg ⁄mL; 5 min, Vector labo-
ratories) and stopped in tap water (10 min). For
double immune-histochemistry, we used secondary
antibodies conjugated with fluorescein-5-isothiocya-
nate or phycoerythrin (PE) conjugated mAb (Dako,
Ely, Cambridge, UK). The slides were finally
embedded in mounting buffer containing 4¢,6-dia-
mino-2-phenylindole (DAPI, Molecular Probes,
Eugene, OR, USA). Single stain sections were
counterstained in hemalaun (1 min, Vector labora-
tories) and then cover-slipped. In controls, the pri-
mary antibody was replaced with pre-immune
mouse serum with positive and negative controls
included. All specimens were evaluated by a
pathologist (D.M.). The intensity and distribution
patterns of the staining reaction were evaluated
by two independent observers, including a gyne-
cological pathologist (D.M.), using the semi-quanti-
tative immunoreactive score (IRS), as previously
described,13 and used to assess steroid receptors 14
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and cathepsin D 15 expression in human endome-
trial tissue. The IRS was calculated by multiplica-
tion of optical staining intensity (graded as 0 = no,
1 = weak, 2 = moderate and 3 = strong staining)
and the percentage of positive stained cells (0 = no
staining, 1 = <10% of the cells, 2 = 11–50% of the
cells, 3 = 51–80% of the cells and 4 = >81% of
the cells). Evaluation of each specimen was
performed without having any knowledge of the
clinical diagnosis.
Statistics
The spss ⁄ pc software package version 15.0 was used
for collection, processing, and statistical data analy-
sis. Statistical analysis was performed by using
non-parametric Wilcoxon test for matched pairs and
non-parametrical Mann–Whitney U-test for compari-
son of the means. P < 0.05 values were considered
statistically significant.
Results
Dendritic cells in the human decidua were analyzed
by determining five times the number of cells per
field of view with a 25· lens magnification. We
investigated DC density and state of activation in all
collected samples.
Density and Maturation of Decidual Dendritic Cells
In decidua of normal term placentas, a median num-
ber of five DC expressing DC-SIGN was seen. Com-
pared to normal term placentas, a significant
upregulation of DC expressing DC-SIGN was deter-
mined in the decidua of HELLP placentas (P = 0.002)
with a median of 18, whereas DC-SIGN was
downregulated non-significantly in IUGR patients
(P = 0.061). No significant changes were seen in pre-
eclamptic decidual tissue compared to normal control
placentas [(P = 0.255); median of four DC-SIGN+
cells per field of view). The expression of DC-SIGN in
normal, HELLP and IUGR placentas is shown in
Fig. 1a–c. Fig. 1d summarizes these results.
The median of decidual DC staining for DEC-205 in
control placentas was four cells per field of view
(Fig. 2a). Staining for DEC-205 was significantly
increased in HELLP placentas (P = 0.001) with a med-
ian density of 10, whereas IUGR placentas showed a
lower expression (P = 0.052; median = 3) (Fig. 2b,c).
In pre-eclamptic placentas, we saw a non-significantly
reduced amount of DC staining positive for DEC-205
(P = 0.226; median = 3) as compared to normal
placentas. These results are shown in Fig. 2d.
In decidual tissue of normal term control
placentas, DC positive for DC-LAMP had a rather
high density with a median of 19.5 (Fig. 3c). We
40
(a)
(c) (d)
(b)
* P = 0.002
30
DC-SIGN
20
0
Control HELLP IUGR PE
10 Fig. 1 Expression of DC-SIGN in normal (a),
HELLP (b) and IUGR (c) placentas, all pictures
10x lens. A summary of staining results is
presented in 1 (d).
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noted a complete abrogation of DC-LAMP in HELLP
patients (P = 0.009) (Fig. 3b). There was no
significant decrease of DC-LAMP in IUGR (P = 0.109;
median = 7) as well as PE placentas (P = 0.301; med-
ian = 16.5). These findings are summarized in
Fig. 3c. A representative serial section stained for the
different DC markers is shown in Fig. 4.
Functional Properties of Decidual Dendritic Cells
and Natural Killer (NK) Cells and Their Interaction
We encountered a high proportion of DC-SIGN
positive DC in HELLP placentas and examined
whether these cells colocalized with NK-cells at
the feto-maternal interphase. We saw a distinctive
(a) (b)
(c) (d)
40
* P = 0.001
30
DEC-205
20
0 Control HELLP IUGR PE
10Fig. 2 Expression of DEC-205 in normal (a)
HELLP (b) and IUGR (c) placentas, all pictures
10x lens. A summary of staining results is pre-
sented in 2 (d).
(a) (b) 
(c)
50 
* P = 0.009 
40 
DC-LAMP 
30 
10 
0 Control HELLP IUGR PE 
20 
Fig. 3 Expression of DC-LAMP in normal (a)
and HELLP (b) placentas, both pictures 10x
lens. A summary of staining results is
presented in 3 (c).
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decidual zone of interaction between DC-SIGN+ DC
and CD56+ NK-cells that was visible exclusively in
HELLP placentas and was completely absent in
normal controls (Fig. 5). DC-SIGN+ DC in HELLP
placentas also expressed vascular endothelial cell
growth factor receptor (VEGFR) -1 & -2. For
VEGFR-2, we saw strong costaining in the
immediate proximity of sections of decidual
vasculature. A pattern that was less prominent for
VEGFR-1 (data not shown). In normal controls,
VEGFR-2 was expressed, but did not costain with
DC-SIGN (Fig. 5).
Taken together, we encountered a different
pattern of distribution and state of activation at the
feto-maternal interphase of pregnancies with HELLP
syndrome compared to normal pregnancies as well
as pregnancies complicated by IUGR or PE. Further-
more, we saw an interaction zone between NK-cells
and DC-SIGN+ DC exclusively in HELLP placentas.
In these placentas, DC-SIGN+ DC costained for
VEGFR, in contrast to normal controls.
Discussion
An immunological contribution towards placental
gestational diseases has been suspected for many
years. We investigated the role of DC within the
immunological equilibrium at the feto-maternal
interphase. To asses DC density and state of matura-
tion, we chose three characteristic DC surface mole-
cules: The C-type lectin-receptor DEC-205 is fairly
ubiquitously expressed on immature DC and is
mildly upregulated upon maturation.16 DC-SIGN,
from the same macrophage mannose receptor family
of C-type lectins, is a molecule that is specifically
expressed on immature DC. Its expression, however,
is downregulated upon maturation.17 DC-SIGN has
also been put forward as a putative functional player
in immunological pregnancy recognition in rhesus
macaques.18 The third marker DC-LAMP constitutes
a surrogate marker for mature, immunogenic DC.19
In this study, histochemical staining showed no
significant changes in DC maturation markers in
pre-eclamptic and growth restricted pregnancies
compared to normal controls. However, patients
who developed HELLP syndrome showed a markedly
different DC morphology in their placentas. We
detected more decidual DC that stained almost
entirely positive for DC-SIGN, and therefore exhib-
ited an immature phenotype. This result is in con-
cordance with data showing a high number of
proliferating DC-SIGN positive DC in early human
pregnancy.20 Although the extent to which normal
first-trimester decidual DC express DC-SIGN is under
scientific dispute, there is consensus regarding DEC-
205 as a decidual DC-marker.12 To the best of our
knowledge, our results represent the first data show-
ing the expression of the unique DC maturation
marker DC-LAMP in human decidua. The lysosome-
associated membrane glycoprotein, DC-LAMP has
been used to characterize mature DC in human can-
cerous tissue and is usually expressed upon encoun-
ter of danger signals.21,22
HELLP syndrome has been considered in some
parts as a variant of PE. Its pathophysiology remains
elusive, although an immunological contribution is
suspected.3 A systemic immune dysbalance with an
emphasis on T helper pathways has been described
for PE.23,24 In this study, we are able to demonstrate
a significant increase in DC-SIGN+ DC and decrease
in DC-LAMP+ DC restricted to HELLP syndrome
derived placentas. PE derived placentas did not show
any significant difference in the maturation pattern
of DC. We speculate that this DC-SIGNhigh,
DC-LAMPlow pattern of decidual DC might be due to
an increased apoptotic activity in HELLP syndrome.
Pre-eclampsia, as well as HELLP-syndrome, is known
to exhibit increased apoptosis of trophoblastic tissue,
although to a different degree.25 Without further
maturation stimuli, apoptotic cell material is known
to skew DC-maturation processes into a tolerogenic
DEC-205
DC-SIGN
DC-LAMP
x10
x 25
Fig. 4 Serial section of a representative HELLP placenta stained for
DEC-205, DC-SIGN and DC-LAMP. Left column 10· magnification. Right
column 25· magnification.
SCHOLZ ET AL.
American Journal of Reproductive Immunology 60 (2008) 238–245 ª 2008 The Authors
242 Journal compilation ª 2008 Blackwell Munksgaard
phenotype and foster cross-priming of exogenous
cell material by DC.26,27 There is accumulating evi-
dence that there is an intensive cross talk between
DC and NK-cells in which lytic behavior and cyto-
kine secretion of NK-cells are influenced by the acti-
vation pattern of DC.11,28 Our morphological data
suggest an intimate relationship between DC and
NK-cells in HELLP syndrome. Uterine NK-cells are
known to play a central role in placentation ensur-
ing proper vascularization by secretion of an array of
angiogenic factors and by inducing vascular growth
in the decidua.29 The close interaction we observed
in HELLP placentas might therefore reflect a com-
pensatory immunological process to foster vasculari-
zation of an otherwise underperfused placenta. A
contribution of DC towards vascularization in
HELLP-syndrome was also seen for VEGFR1&2 as
these receptors were coexpressed by a subset of DC-
SIGN+ DC in HELLP syndrome decidua. In tumori-
genesis, DC contribute to neovascularization via
secretion of angiogenic factors.30,31 Increased
sVEGFR-1&-2 secretion has been shown for placen-
tal tissues from pregnancies complicated by hyper-
tensive disorders.32 Decidual DC display a distinct
state of activation and our data support evidence
that alternatively activated DC play a role within
angiogenetic networks that are altered in insufficient
placentation.33 Taken together, we encountered a
DC-SIGNhigh, DC-LAMPlow phenotype at the feto-
maternal interphase of HELLP patients, that colocal-
Fig. 5 Double staining of DC-SIGN (green)
and CD56, VEGFR-2 (red) respectively. Upper
panel shows costains of one representative
HELLP placenta at the feto-maternal inter-
phase as compared to one representative
normal control (lower panel). Higher
magnification (40·) of the same placenta is
provided in the right column. Arrows indicate
cross sections of maternal blood vessels.
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ized with CD56+ NK-cells and costained for VEGFR.
Whether this constitutes a cause or consequence of a
dysfunctional immune response in these patients
might be difficult to distinguish. Our data suggest a
contribution of decidual DC within this immune
response and might stimulate further studies eluci-
dating their interaction with other immune cells at
the feto-maternal interphase.
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Summary
Human umbilical vein endothelial cells (HUVEC) exposed to the female sex hormone
estradiol show different kinds of effects including increased elasticity, activation
of plasma membrane Na+/H+ exchange, prostacyclin production, prevention of
apoptosis and many others. The aim of this study was the systematic analysis of the
immunolabelling of estrogen receptors (ERs), ERa and ERb, in HUVEC after
stimulation with different commercially available ER modulators and ER agonists
or antagonists. HUVEC response to these substances was shown to be regulated via
ERb. ERa immunolabelling or up-regulation was abrogated after application of
estrogen derivatives, selective estrogen receptor modulators (SERM) and ER agonists
or antagonists. Immunolabelling of ERb was significantly increased by estradiol,
estrone, ethinylestradiol and tumour necrosis factor alpha (TNFa). SERM, such as
Tamoxifen, and pure antagonists, such as ICI 182.780, stimulated ERb in HUVEC at
low concentrations, whereas higher concentrations inhibited ERb immunolabelling.
The pure estrogen receptor agonist 2,3-bis (4-hydroxyphenyl) proprionitrile (DPN)
exhibited its activating potential at low concentrations. In contrast, higher
concentrations resulted in a down-regulation of ERb. Estrogenic effects in HUVEC,
independent of stimulation or inhibition, are mediated via the ERb. SERM such as
Tamoxifen and ER antagonists such as ICI 182.780 act as ER activators in low
concentrations, whereas higher concentrations lead to inhibitory effects.
& 2008 Elsevier GmbH. All rights reserved.
ARTICLE IN PRESS
www.elsevier.de/acthis
0065-1281/$ - see front matter & 2008 Elsevier GmbH. All rights reserved.
doi:10.1016/j.acthis.2008.05.006
!Corresponding author. Department of Obstetrics and Gynecology – Maistrasse, Ludwig-Maximilians University,
Maistrasse 11, D-80337 Munich, Germany. Tel.: +49 89 5160 4266; fax: +49 89 5160 4916.
E-mail address: udo.jeschke@med.uni-muenchen.de (U. Jeschke).
1Both authors contributed equally.
Please cite this article as: Toth B, et al. Estrogen receptor modulators and estrogen receptor beta immunolabelling in human
umbilical vein endothelial cells. Acta Histochem (2008), doi:10.1016/j.acthis.2008.05.006
Introduction
Human endothelial cells are involved in a diversity
of pathophysiological processes, including hemosta-
sis, inflammation and angiogenesis (Park et al.,
2006). Estradiol (E2) and its metabolites are known
to delay the onset of atherosclerosis in women
compared to men (Hillebrand et al., 2006). However,
the cellular mechanisms of these gender-specific
differences remain unclear. Human umbilical vein
endothelial cells (HUVEC) serve as a widely used in
vitro model to study the effects of natural and
synthetic female sex hormones on endothelial cells.
The female sex hormone E2 exerts its actions on
target cells through binding and activation of the
estrogen receptor (ER), a member of the steroid
hormone superfamily of ligand-dependent transcrip-
tion factors. Estradiol and its metabolites bind to
control regions (promoters) of specific gene ele-
ments via receptor–ligand complexes, recruit co-
activators/-repressors and control gene expression
depending on the kinetics of administration (Brosens
et al., 2004; Simoncini et al., 2005). Furthermore,
estrogenic effects on volume, growth and elasticity
of HUVEC (Morales et al., 1995; Hillebrand et al.,
2006), as well as the release of activation markers
such as prostacyclin (Hermenegildo et al., 2005;
Oviedo et al., 2005), nitric oxide (NO) (Florian et al.,
2004), interleukins (Keck et al., 1998), vascular cell
adhesion molecule-1 (Mukherjee et al., 2002; Tatsumi
et al., 2002) and others, (Akarasereenont et al.,
2000; Chen et al., 2002) have been demonstrated.
There is an ongoing discussion as to whether
estrogenic effects are mediated through ERa, ERb or
both. Although Jensen et al. (1998) and Tatsumi
et al. (2002) showed that HUVEC do not express the
classical ERa, other investigators including Herve
et al. (2006); Evans et al. (2002) demonstrated
weak immunolocalisation of both ERa and ERb
mRNA in HUVEC. A diversity of ER activators and
inhibitors exist, each with different potential to
bind to ERa, ERb, or both. The aim of this study was
to analyze the amount of immunolabelling of ERa
and ERb in HUVEC after stimulation with estrogen
derivatives, selective estrogen receptor modulators
(SERM), ER agonists and antagonists using specific
monoclonal antibodies and immunocytochemistry.
Material and methods
Cell culture
HUVEC were obtained from Promocell (Heidel-
berg, Germany) at passage 2 or 3. The cells were
cultivated in phenol red-free endothelial cell
growth medium (ECGM) (Customer formulation,
Promocell, Heidelberg, Germany) containing 10%
fetal bovine serum, 1.0mg/ml hydrocortisone,
0.1 ng/ml endothelial growth factor, 1.0 ng/ml
basic fibroblast growth factor (bFGF). About 2ml
endothelial cell growth substrate, 5ml streptomy-
cin (Biochrom AG, Berlin, Germany) and 5ml
amphotericin B (Biochrom AG, Berlin, Germany)
were added per 500ml of medium.
HUVEC were used for experiments between
passages 3 and 7. All cell cultures were maintained
in a humidified 5% CO2 atmosphere at 37 1C. HUVEC
were incubated with E2, estrone, ethinylestradiol
(EE), Tamoxifen, ICI 182.780 and 2,3-bis (4-hydro-
xyphenyl) proprionitrile (DPN) as well as tumour
necrosis factor alpha (TNFa) in different concentra-
tions (0–2000 nmol/ml) (Table 1) and cultivated for
up to 72 h on chamber slides (Quadripermm Nunc,
Wiesbaden, Germany). These concentrations are
related to physiological estrogen concentrations in
pregnant human females. Cells were fixed with
methanol/ethanol (50%/50%) (Merck, Darmstadt,
Germany). Chamber slides were then dried,
wrapped and stored at !80 1C as described by Toth
et al. (2008) until required. The Human Investiga-
tion Review Board of the Ludwig-Maximilians-
University Munich approved the study.
ARTICLE IN PRESS
Table 1. Substances used for HUVEC stimulation
Substance Concentrations Source
17b-Estradiol 10, 1, 0.1, 0.01,
0.001 nmol/ml
Sigma-Aldrich,
Munich,
Germany
Ethinylestradiol (EE) 1800, 1000, 500,
100, 10, 1,
0.1 nmol/ml
Jenapharm,
Jena,
Germany
Estrone 1000, 500, 100,
10, 1, 0.1 nmol/ml
Sigma-Aldrich,
Munich,
Germany
DPN 500, 100, 10, 1,
0.1 nmol/ml
Tocris, Bristol,
UK
ICI
182,780 ¼ Fulvestrant
500, 100, 10, 1,
0.1 nmol/ml
Tocris, Bristol,
UK
Tamoxifen 500, 100, 10, 1,
0.1 nmol/ml
Sigma-Aldrich,
Munich,
Germany
TNFa 10, 1, 0.1 ng/ml Sigma-Aldrich,
Munich,
Germany
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Immunocytochemistry
Immunolocalisation of ERa and ERb was analyzed
by using specific monoclonal antibodies and an
avidin biotin complex (ABC) labelling kit (Vectastain
Elite mouse-IgG-Kit, Vector, Burlingame CA, USA)
employed according to manufacturer’s instructions.
All reagents are from this kit unless otherwise
specified. In this study we used monoclonal anti-
bodies against ERb (Clone: PPG5/10, Isotype: mouse
IgG2a, dilution: 1:600, Serotec, Du¨sseldorf, Ger-
many) and ERa (Clone: ER1D5, Isotype: mouse IgG1,
dilution: 1:50, Immunotech, Prague, Czech Repub-
lic).
After thawing, cells were briefly fixed with
formalin (Merck, Darmstadt, Germany; 5% in phos-
phate buffered saline (PBS), 5min). Slides were
incubated in 3% methanol/H2O2 for 30min to inhibit
endogenous peroxidase activity and treated with
1.5% goat serum/PBS for 20min to reduce non-
specific background staining. Incubation with the
primary antibody was performed overnight at 4 1C.
Sections were then incubated with biotinylated
secondary anti-mouse antibody (1:200) for 1 h and
then with avidin biotin peroxidase complex (1:25)
(ABC) prepared according to manufacturer’s in-
structions for 45min (Vectastain-Elite-ABC Kit,
Vector Laboratories, Burlingame CA, USA). Labelling
was revealed by incubation with 1mg/ml diamino-
benzidine/H2O2 (Dako, Hamburg, Germany) for
5min and the reaction stopped by washing in tap
water for 10min. Sections were counterstained in
hematoxylin for 1min, rinsed in tap water for 5min
followed by distilled water and then coverslipped in
Aquatex (Merck, Darmstadt, Germany). All steps
were performed at room temperature and all
dilutions and thorough washes between stages were
performed using PBS unless otherwise stated. In
negative controls, the primary antibody was re-
placed with pre-immune mouse serum. Labelling
was performed in a single run with identical staff,
equipment and chemicals, and a total of six
independent experiments were performed (n ¼ 6).
Positive and negative controls were always in-
cluded. As a positive control we used the ER-
expressing breast cancer cell line MCF7. The slides
were finally mounted in Aquatex mounting media
(Merck, Darmstadt, Germany) and examined using a
Zeiss Axiophot photomicroscope (Carl Zeiss, Jena,
Germany). From each section, five digital pictures
were captured randomly at 200-fold magnification
using a 3CCD color camera (Axiocam). Labelling
intensity was assessed using a semi-quantitative
score by counting the absolute percentage of
positively labeled cells. Two independent observers
blinded to sample identity evaluated the specific
immunocytochemical labelling reaction. For each
condition, between six and nine independent speci-
mens were evaluated.
Statistics
The SPSS/ PC software package (SPSS, Chicago,
IL, USA) version 15.0 was used for data collection,
processing and statistical data analysis. Statistical
analysis was performed using the non-parametrical
Mann–Whitney U signed rank test for comparison of
the means. po0.05 was considered statistically
significant.
Results
Estradiol
Estradiol acts as a natural ER ligand (ERa and
ERb). HUVEC stimulated with 1, 10 and 100 pmol/ml
and 1, 10, and 100 nmol/ml E2, respectively,
showed no immunopositivity of ERa after cultivation
for up to 72 h. In contrast, ERb immunolabelling was
already seen after cultivation for up to 72 h and
could be up-regulated by administration of increas-
ing amounts of E2, as indicated in Figure 1.
Estrone
Estrone is known as one of the natural metabo-
lites of E2. HUVEC stimulated with 0.1, 1, 10, 100,
500 and 1000 nmol/ml estrone showed significant
up-regulation of ERb compared to unstimulated
controls (p ¼ 0.043 for 0.1, 1, 100 and 500 nmol/ml
and p ¼ 0.042 for 10 and 1000 nmol/ml, respec-
tively, Figure 2). Stimulation with 0.1, 1 and
10 nmol/ml estrone led to ERb immunolabelling in
70–80% of all cells investigated, whereas stimula-
tion with 100, 500 and 1000 nmol/ml estrone led
to immunopositivity of ERb in over 90% of HUVEC.
Ethinylestradiol
Oral contraceptives contain ethinylestradiol (EE),
the most widely used synthetic estrogen receptor
activator. Up-regulation of ERb immunolabelling
was seen after stimulation with 1, 10 and
100 nmol/ml EE (Figure 3). This up-regulation was
significant when compared to unstimulated controls
(p ¼ 0.043). Expression of ERb was seen in 50–60%
of HUVEC investigated and was not up-regulated by
administration of higher EE concentrations.
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Tamoxifen (SERM)
Tamoxifen is a widely used SERM, especially in
treatment regimes of ER positive breast cancer
patients. HUVEC stimulated with 0.1 and 1 nmol/ml
Tamoxifen showed significant up-regulation of ERb
compared to non-stimulated controls (p ¼ 0.043),
whereas addition of 10 and 100 nmol/ml Tamoxifen
had no significant influence on ERb immunolabelling
(Figure 4). In contrast, 500 and 680 nmol/ml
Tamoxifen significantly reduced ERb immunolabel-
ling in HUVEC (p ¼ 0.042 and 0.043, respectively).
Stimulation with 0.1 and 1 nmol/ml Tamoxifen lead
to ERb immunolabelling in 35–45% of all cells
investigated compared to 20–25% in non-stimulated
controls. Higher concentrations of Tamoxifen (500
and 680 nmol/ml) reduced ERb immunopositivity to
5–10% of cells.
ICI 182.780
Blocking of the 17b-estradiol receptor can by
achieved using ICI 182.780, a pure estrogen recep-
tor antagonist. HUVEC stimulated with 0.1 and
1 nmol/ml ICI 182.780 showed significant up-regula-
tion of ERb compared to non-stimulated controls
(p ¼ 0.042 and 0.043, respectively). Addition of
10 nmol/ml ICI 182.780 had no significant influence
on the amount of ERb immunopositivity, whereas
100 and 500 nmol/ml ICI 182.780 significantly
reduced ERb immunolabelling in HUVEC (p ¼ 0.043
Figure 5). Stimulation with 0.1 and 1 nmol/ml ICI
182.780 lead to ERb immunolabelling in 35–70% of
all cells investigated compared to 20–25% of
controls. In contrast, administration of higher ICI
182.780 concentrations (100 and 500 nmol/ml)
reduced ERb immunolabelling to 10–15%.
2,3-bis (4-hydroxyphenyl) proprionitrile
(DPN) (pure estrogen receptor agonist)
HUVEC stimulated with 0.1, 1 and 10 nmol/ml
DPN resulted in significant up-regulation of ERb
compared to non-stimulated controls (p ¼ 0.042,
0.043 and 0.043) (Figure 6). Addition of 100 and
500 nmol/ml DPN had no significant influence on
ERb immunolabelling, whereas concentrations of
2000 nmol/ml DPN reduced significantly ERb immu-
nolabelling in HUVEC (p ¼ 0.042). HUVEC stimu-
lated with 0.1, 1 and 10 nmol/ml DPN showed
immunolocalisation of ERb in 35–50% of all cells
investigated compared to 20–25% of controls. In
contrast, high concentration of DPN (2000 nmol/ml)
reduced ERb immunolabelling to nearly 15%.
Tumour necrosis factor alpha
HUVEC stimulated with 1, 10 and 100 nmol/ml
TNFa showed significant up-regulation of ERb
in all cases compared to non-stimulated
controls (p ¼ 0.011, 0.018 and 0.011, respectively)
(Figure 7). After HUVEC stimulation with 1,
10 nmol/ml TNFa immunolabelling of ERb was seen
in 80–90% of all cells investigated and was not
ARTICLE IN PRESS
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Figure 1. ERb in non-stimulated HUVEC cells (a). Arrows
indicating nuclei with strong and weak immunolabelling
(counted as positive) and nuclei without immunolabelling
(counted as negative). (b) A representative negative
immunolabelling for ERa. Scale bar ¼ 200 mm.
B. Toth et al.4
Please cite this article as: Toth B, et al. Estrogen receptor modulators and estrogen receptor beta immunolabelling in human
umbilical vein endothelial cells. Acta Histochem (2008), doi:10.1016/j.acthis.2008.05.006
further up-regulated by administration of 100 nmol/
ml TNFa.
Discussion
In our study, we were able to demonstrate that
estrogen derivatives, SERM as well as pure ER
agonists or antagonists, act via ERb in HUVEC,
whereas ERa seems not to be involved in this
process. Metabolites of E2, as well as the synthetic
estrogen EE, lead to an up-regulation of ERb protein
immunolocalisation in a dose-dependent manner.
Furthermore, SERM and ER antagonists act as ER
activators when administered to HUVEC in low
amounts, whereas high concentrations lead to ER
down-regulation. With regard to ER agonists,
administration of high concentrations lead to a
down-regulation of ERb and only low concentrations
activated ERb immunopositivity in HUVEC. The
cellular effects of estrogens are mediated by
binding to nuclear receptors (ER) that activate
transcription of genes involved in cellular growth
control. In a variety of cells ERa and ERb mediate
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Figure 2. ERb immunopositivity is increased in HUVEC stimulated with 1 nmol/ml estrone (a) and 100 nmol/ml estrone
(b). A summary of immunolabelling results is presented in (c). Scale bar ¼ 200 mm.
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these effects in conjunction with a number of co-
activators. Both receptors can directly interact with
other members of the steroid receptor superfamily.
A cross-talk exists between the estrogen-signalling
pathways and the downstream signalling cascade
initiated by growth factors, such as epidermal
growth factor and insulin-like growth factors.
Estrogens are also involved in the pathogenesis of
a variety of neoplastic and non-neoplastic diseases,
including breast cancer, endometrial cancer, en-
dometriosis and uterine fibroids (Dhingra, 1999). In
addition, estrogens are acquired risk factors for
venous thromboembolism and endothelial cells play
a major role in the pathogenesis of thrombophilia
(Toth et al., 2007).
The concentration-dependent modulator effect
of SERM in HUVEC could potentially arise from
saturation of the ERb by co-regulators which trigger
degradation or maintenance of a bound agonist for
a period of time long enough to trigger removal and
degradation (Jordan and O’Malley, 2007). Further
studies are needed to investigate these potential
mechanisms, but are beyond the scope of this
paper.
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Figure 3. ERb immunopositivity is increased in HUVEC stimulated with 10 nmol/ml ethinylestradiol (a). A summary of
immunolabelling results is presented in (b). Scale bar ¼ 200 mm.
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Our results further support earlier investigations on
ER expression in HUVEC. Ling et al. (2006) published
data on the effects of 17b-estradiol on growth and
apoptosis in HUVEC. They were able to demonstrate
that E2 enhanced HUVEC growth in serum-enriched
media in a concentration-dependent manner. The
authors concluded that E2 effects are possible
cellular mechanisms underlying female gender-asso-
ciated cardiovascular protection. However, no differ-
entiation between ERa and ERb expression was made.
With regard to the effects of E2 and its metabolites
on ERb immunolabelling in our study, we conclude
that the known estrogenic effects in HUVEC were
mediated by the non-classical ERb.
Nonetheless, conflicting results on ERa and ERb
expression in HUVEC do exist (Jensen et al., 1998;
Tatsumi et al., 2002; Herve et al., 2006). An
ERa variant named ER46 was localized in the plasma
membrane of HUVEC and it modulates membrane-
initiated estrogen actions, including endothelial
nitric oxide synthase (eNOS) activation (Li et al.,
2003). Further studies on ER46 expression and
activation are necessary to elucidate possible
interactions between ERb and ER46.
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Figure 4. ERb immunopositivity is increased in HUVEC stimulated with 0.1 nmol/ml TNFa (a) and 10 nmol/ml TNFa (b).
A summary of immunolabelling results is presented in (c). Scale bar ¼ 200 mm.
Estrogen receptor modulators and human endothelial cells 7
Please cite this article as: Toth B, et al. Estrogen receptor modulators and estrogen receptor beta immunolabelling in human
umbilical vein endothelial cells. Acta Histochem (2008), doi:10.1016/j.acthis.2008.05.006
So far, there are no systematic data on the effects
of SERM and pure ER antagonists on ERb protein
expression. We were able to show adverse effects
depending on the administered concentration of
SERM or pure ER antagonists. Both SERM and pure ER
antagonists acted as ERb activators in low concen-
trations and as inhibitors in high concentrations. Lei
et al. (2001) investigated the regulation of growth-
regulated oncogene a (GROa) expression by E2 in
HUVEC. Tamoxifen abrogated the down-regulation
of GROa induced by E2. The authors concluded that
GROa is regulated by ERa, as Tamoxifen abolished
the E2 effect in more than 50% of cells. ERb
expression was not investigated. Our results indi-
cate that Tamoxifen regulates ER expression
through ERb in HUVEC.
Besides SERM (like Tamoxifen), pure ER antago-
nists (i.e. ICI 182.780) were investigated to
antagonize possible estrogenic effects on HUVEC
(Hayashi et al., 1995; Florian et al., 2004; Oviedo
et al., 2005). HUVEC incubated with five different
concentrations of ICI 182.780 showed decreased
cell viability and increased apoptosis (Soares
et al., 2003). ICI 182.780 impaired angiogenesis by
ARTICLE IN PRESS
0
5
10
15
20
25
30
35
40
45
50
680 nmol/ml
Tamoxifen
500 nmol/ml
Tamoxifen
100 nmol/ml
Tamoxifen
10 nmol/ml
Tamoxifen
1.0 nmol/ml
Tamoxifen
0.1 nmol/l
Tamoxifen Control
ER
 b
et
a 
(%
)
∗
Figure 5. ERb immunopositivity is increased in HUVEC stimulated with 1 nmol/ml tamoxifen (a), whereas cells
stimulated with 100 nmol/ml tamoxifen (b) showed no significant changes compared to non-stimulated controls. A
summary of immunolabelling results is presented in (c). Scale bar ¼ 200 mm.
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preventing branching and capillary-like tubule for-
mation and by activating apoptotic pathways in
endothelial cells (Soares et al., 2003). We were able
to demonstrate that ICI 182.780 acts as a pure ER
activator in low concentrations, whereas its poten-
tial as ER antagonist is only present in high
concentrations.
To our knowledge, there are no published data on
the effects of the pure ERa and ERb agonist 2,3-bis
(4-hydroxyphenyl) proprionitrile (DPN) on HUVEC.
However, as expected, an up-regulation of ERb
immunolabelling was seen at low concentrations,
whereas administration of high concentrations leads
to a down-regulation of ERb.
There are several investigations on the effects of
TNFa on HUVEC (Miro et al., 2000; Silva et al., 2003;
Ling et al., 2006; Pihusch et al., 2006; Szczepanski
et al., 2007). However, as far as we are aware, no
effects of TNFa administration on ERb expression
have been published. We were able to demonstrate
that TNFa leads to an activation of ERb expression
up to 80–90% of investigated HUVEC, which could
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Figure 6. ERb immunopositivity is increased in HUVEC stimulated with 0.1 nmol/ml ICI 182.780 (a), whereas cells
stimulated with 100 nmol/ml ICI 182.780 (b) showed significant reduced immunolabelling of ERb compared to non-
stimulated controls. A summary of immunolabelling results is presented in (c). Scale bar ¼ 200 mm.
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not be further up-regulated by higher amounts of
TNFa.
In summary, our study showed that effects of
natural and synthetic female sex hormones as
well as SERM, pure ER agonists and antagonists on
HUVEC are mediated via the ERb pathway. Estrogen
and its metabolites up-regulated ERb protein
expression in a concentration-dependent manner,
whereas pure ER agonists and antagonists exhibit
adverse effects depending on the concentrations
investigated.
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Glycodelin A Induces a Tolerogenic Phenotype
in Monocyte-Derived Dendritic Cells In vitro
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Introduction
Viviparity poses an immunological paradox as fetal
tissues express alloantigens encoded by paternal
polymorphic major histocompatability complex
(MHC)-genes. The growing fetus is not merely toler-
ated by the maternal immune system during the
time of pregnancy, but there is growing evidence
that the unique immunological equilibrium at the
feto-maternal interface plays an integral part during
placentation.1 Many factors that influence this
unique immunological relationship are known
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Problem
Successful mammalian pregnancy requires a delicate immunological bal-
ance at the feto-maternal interface that allows the semi-allogeneic fetus to
grow, while protecting mother and child from environmental pathogens.
As in other mucosal tissues, antigen-recognition and -handling by profes-
sional antigen-presenting cells such as dendritic cells (DC) determine the
course of the subsequent immune response. DC at the feto-maternal inter-
face help shape this immunological equilibrium. Endometrial tissue
secretes high quantities of glycodelin A (GdA) during the so-called fertile
window (i.e. the time of implantation of the blastocyst).
Method of study
We investigated the effect of GdA on monocyte-derived DC (moDC)
regarding surface marker expression, endopinocytotic activity, cytokine
profile as well as lymphoproliferative activity.
Results
Upon pretreatment with GdA and subsequent maturation with tumor
necrosis factor-a and interleukin (IL)-1b, moDC displayed a reduced
expression of costimulatory molecules, an unchanged major histo-
compatibility complex-II expression and persistence of DC-SIGN positive
cells. GdA-pretreated moDC had a higher endopinocytotic activity, an
increased IL-10 production and a dose-dependent reduction in lympho-
proliferative activity. GdA incubation alone did not alter the immature
phenotype.
Conclusion
Our results suggest a model in which the human endometrium secretes
high quantities of GdA during implantation and thereby helps to shape
the unique immunological interaction between mother and fetus via
decidual DC.
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today. There are accumulating data that dendritic
cells (DC) play a central role within this immuno-
logical feto-maternal network.2,3 There is also
evidence that maternal T cells are aware of fetal
alloantigens, but acquire a transient state of antigen-
specific tolerance during pregnancy.4 DC are profes-
sional antigen-presenting cells (APC) and central
regulators of immunity.5 They can initiate primary
T-cell immune responses by antigen-uptake and pro-
cessing in inflamed peripheral tissues followed by
migration to T-cell rich areas of peripheral lymph
nodes, where they prime T cells via antigen presen-
tation and simultaneous costimulation. At the same
time, there is evidence that DC also play a role in
maintaining peripheral tolerance and act either as
inducers or as suppressors of antigen-specific immu-
nity.6,7 The human decidua has long been known to
be a tissue of antigen-presenting properties.8 Only
recently, however, a set of data is accumulating
regarding the role of professional APC in the human
placenta.2,9,10 The capacity of DC to induce immu-
nity or tolerance seems to be dependent on their
state of activation and can be influenced by exoge-
nous factors.11 DC found at the feto-maternal inter-
face have been shown to exhibit an immature or
semi-mature phenotype with a high proportion of
cells expressing the C-type lectin receptor
DC-SIGN.12 Glycodelin A (GdA), formerly known as
placental protein 14, constitutes one of many factors
known today that influence the immunological
interaction between mother and fetus.1 GdA, a
member of the family of lipocalines, is a secreted
glycoprotein found in variable concentrations in the
human genital tract. One of the main tissues of
GdA-secretion is the human endometrium. Endo-
metrial secretion of GdA is strictly dependent on the
rise of progesterone levels during the luteal phase of
the menstrual cycle and during early pregnancy and
is secreted in high quantities (more than 105 lg ⁄L in
amniotic fluid of early human pregnancy).13 GdA is
known to have direct immunomodulatory effects. In
a seminal series of studies, it has been shown to sup-
press reactivity of phytohaemagglutinin-stimulated
lymphocytes in vitro.14–16 GdA has also been shown
to inhibit directly NK and B-cell function in vitro.17,18
But, only recently, scientific interest was drawn to
the fact that GdA might not be merely damping
immune responses by direct blocking of NK- and
T-cell function, but rather skewing the immune
response to allow the fetal semi-allograft to implant
into the endometrial tissue. Its immunomodulatory
effects on T cells are mediated by binding to CD45 in a
carbohydrate-dependent manner.19 In stimulated T
cells, it preferentially inhibits expression of interferon
(IFN)-c, as opposed to interleukin (IL)-5 and IL-4 by
reduced expression of chemokine (C-X-X motif)
receptor 3 (CXCR3) and reduced repression of the
transcriptional factor GATA-3.20 Further suppressive
effects are known regarding NK- and B cells.18,21 So
far, no effects have been described regarding DC,
although a glycodelin receptor has been postulated on
monocytes.22 Only recently, a proapoptotic gene cas-
cade has been characterized in monocytic cell lines
and primary human monocytes upon GdA stimula-
tion.23 On the basis of the hypothesis that GdA might
influence DC present at the feto-maternal interface
and therefore foster successful implantation of the
human blastocyst, we investigated the effect of iso-
lated human GdA on phenotype, endopinocytosis,
cytokine-secretion and lymphoproliferative capacity
on monocyte-derived DC (moDC).
Materials and methods
Cell culture
All cell cultures were maintained in RPMI 1640
medium (Biochrom, Berlin, Germany) supplemented
with 2% heat inactivated human pooled AB serum
(BioWhittaker, Walkersville, MD, USA), 2 mm l-glu-
tamine (Life Technologies, Paisley, UK), 50 U ⁄mL
penicillin, and 50 mg ⁄mL streptomycin (both from
Sigma, Munich, Germany), hereafter referred to as
complete medium. All cultures were maintained at
37!C, 5% CO2 and 95% humidity.
Isolation and Culture of Human DC
Dendritic cells were generated from peripheral blood
mononuclear cells (PBMC), as described elsewhere,
with minor modifications.24 In brief, PBMC were
isolated from healthy voluntary donors by standard
density-gradient centrifugation on Ficoll separating
solution (Biochrom), washed three times and resus-
pended in complete medium. PBMC (5 · 106 ⁄mL)
were allowed to adhere in 75-cm2 culture flasks for
60 min. Non-adherent cells were removed by pipett-
ing. After an overnight incubation, the initially
adherent cells were transferred into 6-well plates
(1.5 · 106 cells ⁄2 mL) in fresh complete medium
supplemented with 1000 IU ⁄mL granulocyte–macro-
phage colony-stimulating factor (GM-CSF) and
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500 IU ⁄mL IL-4. A sample of generated moDC was
assessed for purity (especially bystander lympho-
cytes) before further use.
Reagents
GM-CSF (Leukine") was purchased from Immunex
(Seattle, WA, USA), IL-4 from Promega (Madison, WI,
USA), and tumor necrosis factor-a (TNF-a) from R&D
Systems (Wiesbaden, Germany); IL-1b was obtained
from Strathmann Biotech (Hannover, Germany).
Purification of GdA
Glycodelin A was purified from pooled human mid-
trimester amniotic fluid as previously described.25
Briefly, amniotic fluid was loaded onto a diethylami-
noethyl-sepharose column and fractionated on a
50–500 mm NH4HCO3
) gradient followed by gel fil-
tration and a second anion exchange chromatogra-
phy step on Resource Q. Final purification was
obtained by hydrophobic interaction chromatography
on Octyl-Sepharose and Resource-Phe (all columns:
GE Healthcare, Freiburg, Germany). All batches were
tested for purity by Western blot (primary goat-anti-
body: sc-122291; Santa Cruz, Heidelberg, Germany)
(Fig. 1). Biotinylated secondary anti-goat anti-
bodies (PK-6105) and Avidin-Alkaline Phosphatase
Complexes (AK-5000) were purchased at Vector Lab-
oratories (Burlingame, CA, USA) and were used
according to the manufacturer’s instructions. Final
tagging was performed using 5-bromo-4-chloro-
3-indolyl-phosphate and nitroblue tetrazolium
(BCIP ⁄NBT; Sigma) yielding purple staining of
labeled bands.
Batches of purified GdA were tested for endotoxin
contamination by its lack of TNF-a induction on
PBMC. All samples were collected from patients who
underwent reduction for polyhydramnia for medical
reasons. The local ethical committee approved the
obtaining and handling of human material.
mAbs and Flow Cytometry
Mouse anti-human monoclonal antibodies (mAbs)
and the appropriate isotype controls were all
obtained from Becton Dickinson (Heidelberg,
Germany). Anti-HLA-DR, (immunoglobulin IgG2b;
APC-conjugated); anti-CD86 (IgG1; phycoerythrin-
conjugated); anti-CD83 [IgG1, fluorescein isothiocya-
nate (FITC)-conjugated]; anti-CD14 [IgG2b; peridinin
chlorophyll protein (PerCP)-conjugated]. For FACS-
analysis, 105 moDC suspended in 100 lL of phos-
phate-buffered saline (PBS) were incubated with
10 lL of the fluorochrome-labeled mAbs for 20 min
on ice. After the staining procedure, the samples
were washed once in PBS and measured immedi-
ately (FACS-Calibur; Becton Dickinson). Data were
analysed using CellQuest Pro software (version
5.2.1; Becton Dickinson).
Endopinocytotic Activity
Cells were washed and endopinocytotic activity was
assessed adding FITC-dextran (0.5 mg ⁄mL) (Mr
40,000) to the culture medium for 30 min at 37!C
(control on ice), as described elsewhere.26 In brief,
immature, untreated DC served as positive controls
when incubated at 37!C. Incubation on ice, on the
other hand, abrogates endopinocytosis and was there-
fore used as a negative control. DC that had been
matured in the presence or absence of 25 lg ⁄mL GdA
or with GdA alone were tested for their ability to take
up FITC-dextran. After 30 min, cells were washed
Fig. 1 High-performance liquid chromatography (HPLC) (a) and wes-
tern blot analysis (b) of purified glycodelin A (GdA). First GdA was puri-
fied using a three-step HPLC isolation protocol described in Materials
and methods. An example of the final isolation step is presented in
(a). GdA fraction is marked with a bar. For protein identification and
purity verification, a Western blot was performed (b) yielding an
appropriate band at 28-kDa. MWM, molecular weight marker.
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three times to eliminate all FITC-dextran attached to
the outer cell membrane and subsequently incorpo-
rated FITC-dextran was analysed by flow cytometry.
Lymphoproliferative Activity
Dendritic cells were harvested and cocultured in
complete medium with a constant number of alloge-
neic non-adherent PBMC (2 · 105 ⁄200 lL) in
96-well round-bottom microtiter plates at ratios
ranging from 1:10 to 1:160. DNA-synthesis was mea-
sured using the Cell Proliferation enzyme-linked
immunosorbent assay (ELISA), 5-bromo-2-deoxyuri-
dine (BrdU; chemiluminescent) (Roche Diagnostics,
Mannheim, Germany). In short, cells were labeled
by the addition of BrdU for 12 hr. BrdU is incorpo-
rated in place of thymidine into the DNA of prolifer-
ating cells. Cells were dried, fixed and the DNA
denatured. Subsequently anti-BrdU, peroxidase-
labeled antibody was added binding to the BrdU
incorporated into the newly synthesized cellular
DNA. The immune complexes were detected by a
subsequent substrate reaction. The reaction product
was quantified by measuring the light emission on a
luminescence ELISA reader (MRX; Dynatech Lab,
Burlington, MA, USA) at 450 nm wavelength.
Cytokine Aecretion
Cytokine secretion was analyzed by ELISA. BD Opt-
EIA# Human IL-10 and Human IL-12 (p40) ELISA
set were purchased from Becton Dickinson and
applied according to the manufacturer’s instructions.
Supernatants of cell cultures were collected 48 hr
after stimulation and analysed.
Statistical Analysis
Data are expressed as median ± S.E.M. Statistical sig-
nificance was determined by the Student’s t-test for
paired samples of original values. Differences were
considered statistically significant for P < 0.05.
Results
Pre-incubation of moDC with GdA Results in
Reduced Maturability
Immature moDC were characterized by the absence
of CD14, CD83, CD86 and intermediate expression
of MHC class II as well as DC-SIGN. To test the
influence of GdA on their maturation processes,
moDC were incubated with 0, 10, 25 or 50 lg ⁄mL
GdA over the course of 24 hr, washed exten-
sively and subsequently matured using a standard
combination of TNF-a (1000 U ⁄mL) and IL-1b
(10 ng ⁄mL).11 After 48 hr, the morphological
changes in the maturation process were assessed by
flow cytometry. moDC that were exposed to GdA
showed a diminished expression of CD83 and CD86
compared to matured DC (Fig. 2). In all tested con-
ditions, moDC stayed negative for CD14 (data not
shown). Incubation with GdA alone had no signifi-
cant effect on the expression of costimulatory mole-
cules. Upon maturation, untreated DC showed the
expected increase in costimulatory- and MHC-mole-
cules as well as a reduced expression of DC-SIGN.
However, moDC that were subject to pretreatment
with GdA only marginally increased the expression
of costimulatory and MHC-II molecules compared to
their unstimulated counterparts. As for DC-SIGN, we
detected a mean of fluorescence intensity that lay in
between matured and immature moDC. In four of
six independent experiments performed, a distinct
DC-SIGN positive population was seen (Fig. 2).
A similar pattern was seen for 50 lg ⁄mL GdA
(data not shown), whereas pre-incubation with
5 lg ⁄mL GdA had only a marginal effect on the sur-
face markers tested. However, no distinct DC-SIGN
positive moDC populations were detected when pre-
incubation was performed with low concentrations
of GdA (data not shown). In all cases, viability of
the cells was assessed using the trypan blue exclu-
sion method and was comparable between the dif-
ferent conditions and time points. At higher
concentrations (starting at 100 lg ⁄mL), we encoun-
tered increasing cytotoxic effects as confirmed by
trypan blue exclusion (data not shown).
Pre-incubation with GdA Leads to Diminished
Endopinocytotic Activity
A functional parameter of immature moDC is their
ability to constantly take up antigen and present it via
MHC molecules without concurrent costimulation.
Upon maturation, however, moDC downregulate
endopinocytosis and present their antigen-content
together with costimulatory molecules in a stable
fashion leading toward immunostimulation.27 To test
the influence of GdA-pretreatment on endopinocytot-
ic activity, moDC were incubated with FITC-dextran
for 30 min and uptake of FITC-dextran was measured
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Fig. 2 Diminished expression of maturation markers and persistence of DC-SIGN after pretreatment with 25 lg ⁄mL glycodelin A (GdA). Monocyte-
derived DC were pretreated with 25 lg ⁄mL GdA for 24 hr and subsequently matured with tumor necrosis factor-a (1000 IU ⁄mL) and interleukin-lb
(10 ng ⁄mL) and were subsequently analysed by flow cytometry after 48 hr, as described in Materials and Methods. One representative experiment
out of six is depicted in the lower segment. Dotted lines indicate isotype-controls. In the upper part, the median mean fluorescence index of all
six experiments is shown accompanied by the standard error of mean (±S.E.M.). Conditions are marked by ± respectively.
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after 24 hr by flow cytometry. Pretreatment with GdA
resulted in persistence of endopinocytotic activity
regardless of external maturation stimuli. A significant
reduction in the capacity to downregulate endopino-
cytosis was detected when comparing matured and
GdA-pretreated moDC (Fig. 3).
Preincubation with GdA Dose Dependently
Reduces Lymphoproliferative Activity of moDC
To determine further the functional properties of
GdA-pretreated and subsequently activated moDC,
we assessed their capacity to stimulate allogeneic-
mixed lymphocytes. DC–T cell ratio was set at 1:10–
1:160. (1:10, 1:40, 1:80, 1:160). At concentrations of
10 lg ⁄mL GdA, lymphoproliferative capacity upon
maturation of moDC was only slightly diminished
compared to matured moDC. At a concentration of
25 lg ⁄mL GdA, subsequently matured moDC
showed a marked reduction in their capacity to pro-
liferate allogenic lymphocytes (Fig. 4). Compared to
unstimulated moDC, GdA alone – without subse-
quent maturation – induced an approximately
two-fold increase in lymphocytic proliferation. These
proliferation rates were comparable to those seen
with subsequent maturation. An increase in GdA
concentration (25 and 50 lg ⁄mL) did not alter the
proliferative behaviour (data not shown).
GdA Pretreament Results in an Increased
Secretion of IL-10 by moDC While Decreasing
IL-12 Secretion
Upon activation, moDC are known to produce IL-12
as well as IL-10 on various stimuli and seem to char-
acterize their immunogenic behaviour.28,29 TNF-a
and IL-1b stimulated moDC showed a median IL-12
p40 secretion of 4256 pg ⁄mL (range: 6859–
2615 pg ⁄mL) and a median IL-10 secretion of
83 pg ⁄mL (range: 165–23 pg ⁄mL). This pattern
changed toward an IL-10-dominant cytokine milieu
once GdA was added before maturation. In this case,
a median IL-12 p40 secretion of 1079 pg ⁄mL (range:
2361–108 pg ⁄mL) was noted, while IL-10 was
detected in a median concentration of 311 pg ⁄mL
(range: 475–197 pg ⁄mL). Low concentrations of IL-
10 were detected in immature moDC [42 pg ⁄mL
(range: 23–55 pg ⁄mL)] and GdA-treated moDC with-
out subsequent maturation [69 pg ⁄mL (range:
80–50 pg ⁄mL)] with only trace IL-12 p40 detectable
in these conditions (Fig. 5). High concentrations of
GdA (50 lg ⁄mL) did not change this cytokine pat-
tern, whereas this effect was not statistically signifi-
cant at concentrations of 5 and 10 lg ⁄mL (data not
shown).
Discussion
In this article, we are presenting data on the
influence of GdA pre-incubation on moDC. This
in vitro model is based on the assumption that ex vivo
generated moDC may exhibit similar physiological
behavior toward human decidual DC, which are
predominantly of myeloid origin.10 We show that
moDC alter their immunological phenotype upon
pretreatment with GdA.
Isolation of GdA
Glycodelin A was isolated and purified from
pooled amniotic fluid by fast protein liquid
chromatography and afterwards checked for purity
and for lipopoysaccharide (LPS) contamination.
High-performance liquid chromatography analyses
of the purified product revealed one main peak
and a small secondary peak in its immediate
proximity. This small peak belonging to the same
protein is known to be caused by changes in
glycosilation e.g. desialization of the same purified
protein.
Fig. 3 Preincubation with 25 lg ⁄mL glycodelin A (GdA) leads toward
persistent endopinocytotic activity regardless of external maturation
stimuli. Dendritic cells were incubated with fluorescein isothiocyanate-
dextran at 37!C for 30 min. Mean data of five experiments are shown.
Data are normalized against controls on ice and shown as multiples of
the mean fluorescence index (·-MFI). Error bars indicate standard
error of mean (S.E.M.). Bracket and asterisk indicate statistical
significance.
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Surface Marker Expression
In our in vitro model, maturation of moDC with
TNF-a and IL-1b led toward a fully matured pheno-
type with high expression of costimulatory mole-
cules (CD83, CD86), MHC-II molecules and
downregulation of CD 209 (DC-SIGN). Incubating
moDC with 25 lg ⁄mL GdA for 24 hr had no influ-
ence on the expression of these surface markers.
Preincubating moDC with GdA, however, changed
Fig. 5 Interleukin (IL)-10 dominant pattern of matured glycodelin A (GdA)-pretreated monocyte-derived dendritic cells (moDC). moDC that are pre-
treated with 25 lg ⁄mL GdA before maturation with tumor necrosis factor-a (TNF-a; 1000 IU ⁄mL) and IL-lb (10 ng ⁄mL) exhibit a IL-10high IL-12low
cytokine pattern, whereas incubation with GdA without subsequent maturation does not lead toward an induction of IL-10. Maturation of DC with
TNF-a and IL-lb alone resulted in an IL-10low IL-12high cytokine pattern. Mean data of six independent experiments are shown. Error bars indicate
standard error of mean (S.E.M.). Bracket and asterisk indicate statistical significance.
Fig. 4 Pretreatment with glycodelin A (GdA) leads toward a dose-dependent reduction in lymphoproliferative activity in spite of subsequent matu-
ration. Monocyte-derived dendrititc cells (moDC) were pretreated with the indicated concentrations of GdA for 24 hr and subsequently matured
with tumor necrosis factor-a (1000 IU ⁄mL) and interleukin-lb (10 ng ⁄mL). moDC were harvested and cocultured with allogenic non-adherent periph-
eral blood mononuclear cells in 96-well microtiter plates at the indicated ratios. 10 lM 5-bromo-2-deoxyuridine was added and its incorporation
was determined after 72 hr of coculture. The data shown represent six independent experiments with the error bars indicating standard error of
mean (±S.E.M.). Data were normalized against conditions in which untreated and matured DC were used in a DC ⁄ T-cell ratio of 1:10.
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the way moDC reacted on maturation stimuli. Com-
pared to standard maturation with TNF-a and IL-1b
alone, we saw a markedly reduced expression of
CD80 and CD83, pointing toward a reduced T-cell
stimulatory capacity. We also detected an intermedi-
ate level of expression for MHC-II molecules upon
pretreatment with GdA. This is consistent with the
notion that semi-matured DC may be tolerogenic
under steady-state conditions.30 Fitting into this pic-
ture was a persistence of DC-SIGN as a marker of
immature moDC. Interestingly, we saw a distinct
DC-SIGN positive population on GdA-pretreated and
subsequently matured moDC in four of six indepen-
dent experiments.
Interaction Between GdA and DC-SIGN
Circumstantial evidence points toward an interaction
between DC-SIGN and GdA. DC-SIGN is a type II
C-type lectin that binds with high affinity distinct
carbohydrate structures, such as glycoconjugates,
with a branch of at least three mannose structures
(high mannose structures) as well as fucosylated
Lewis blood group antigens (e.g. Lewisx).31,32 van
Liempt et al.33 reported that fucosylated Lac-di-NAc-
N-glycans exhibit the highest binding efficiencies to
DC-SIGN compared to a variety of other carbohy-
drate structures. GdA is known to carry all of these
binding partners for DC-SIGN. Apart from high man-
nose structures, glycans found on GdA are blood
group Lewisx and the Lac-di-NAc analog of Lewisx.34
GdA is the only known mammalian glycoprotein
carrying fucosylated Lac-di-NAc-N-glycans, which
happen to be the strongest characterized binding
partner for DC-SIGN and are otherwise only found
on helminths like Schistosoma mansonii.35 Further-
more, functional data support DC-SIGN mediated
actions of GdA. In a recent report, Nonaka et al.36
present repression of LPS-induced maturation of
moDC that was dependent on interaction between
DC-SIGN and Lewis blood group antigens, similar to
those found on GdA. Subsets of myeloid DC are
known to express DC-SIGN upon different stimuli
including IL-10.37 It is therefore tempting to specu-
late that GdA induces an antigen-dependent expres-
sion of DC-SIGN within a subset of moDC. There is
an intriguing similarity between the effects we see
when incubating moDC with GdA to other experi-
ments looking into the behavior of DC toward
Schistosoma egg antigen (SEA) that expresses GdA-typ-
ical Lac-di-NAc-N-glycans.38 In these experiments,
the authors show that SEA inhibits poly-I:C or LPS-
induced DC activation and cytokine production and
down-modulates T helper (Th)1 responses of phorbol
12-myristate 13-acetate-stimulated naı¨ve T cells as
detected with intracellular IL-4 (Th2) and IFN-c
(Th1) flow cytometric staining. Similar to our experi-
ments, the authors see a reduction in IL-12 p40
secretion in LPS or poly I:C stimulated DC upon
simultaneous incubation with SEA, while IL-10
secretion remains high with low concentrations of
SEA. In addition, the authors were able to show
dependence of these effects on interaction with
DC-SIGN. Although there are considerable differ-
ences in the experimental setup (e.g. 24 hr GdA-
preincubation versus simultaneous SEA-incubation),
there seems to be a similar immunological reaction
on DC. In our experiments, we do not prove binding
or signaling via DC-SIGN because of scarcity of puri-
fied human GdA. Recombinant glycodelin, on the
other hand, exhibits a different glycosilation pattern
and may therefore show different binding capacity
and biological actions.
Cytokine Secretion
One of the decisive factors discriminating between
immunostimulatory and tolerogenic DC is their cyto-
kine secretion. moDC have been shown to secrete
IL-12, as one of the pivotal Th1 cytokines, upon var-
ious maturation stimuli.39,40 We were able to show
in previous experiments that moDC secreted IL-12
upon maturation with TNF-a, prostaglandin E2 and
purine derivatives.26 Other groups have identified
cytokine cocktails that induced stabile maturation in
moDC.41 There are data supporting the notion that
IL-12 secretion strictly depends on Toll-like receptor
(TLR)- or CD40-ligation.42 In our experiments, auto-
logous bystander T cells (5–7%) that could not be
eliminated during the adherence-sorting process pro-
vided CD40 ligation. IL-10, the hallmark cytokine
involved in Th2 responses, has been shown to be
produced by DC upon exposure to respiratory anti-
gens, for example.6 Another possible source of IL-10
are (regulatory) T cells, as bystander T cells were
present in our moDC cultures. GdA is known to sup-
press directly T-cell reactivity and to induce Th2
cytokines like IL-4 or IL-13. IL-10, however, was not
measured in these experiments.20,43 Given the purity
of the DC preparation, the most probable source of
IL-10 upon pretreatment with GdA in our experi-
ments seems to be moDC. There is conflicting
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evidence on the induction of apoptosis in monocytes
by GdA.23,43 The secretion of IL-10, we saw in our
experiments, however, argues against a direct cyto-
pathic effect of GdA on moDC. Moreover, we con-
trolled viability by trypan blue exclusion leading
toward comparable results at the GdA-concentra-
tions used. At higher concentrations, however, we
also came across cytopathic effects, although we did
not distinguish between apoptosis and necrosis. In a
recent publication on this issue, it was observed that
TNF-a stimulation of monocytes leads toward an acti-
vation of NF-jB, rescuing monocytes from apoptosis
induced by recombinant GdA.23 In these experi-
ments, TNF-a-induced NF-jB activation was signifi-
cantly reduced upon incubation with recombinant
GdA. As IL-12 is expressed under an NF-jB promo-
tor, this fact may shed some light on intracellular
signaling of IL-12 secretion upon GdA-pretreatment.
A similar cytokine pattern, as we have seen upon
GdA preincubation, has been reported for mononu-
clear cells isolated from human deciduas.44 Isolated
(CD45+; CD3); CD14); CD16); CD19); CD20);
CD56); HLA-DRbright) DC from early human preg-
nancy were shown to secrete less IL-12 upon LPS-
activation than their counterparts isolated from
peripheral blood.45 Spontaneous secretion of Th2
cytokines including IL-10 has been reported for
mononuclear cells during the course of preg-
nancy.46,47 IL-10 is associated in mice and humans
in the mechanisms of maternal tolerance of normal
pregnancy.48,49 IL-10-deficient mice, however, are
fertile, but show an altered growth trajectory in utero
and after birth.50 Taken together, the morphological
features regarding surface marker expression as well
as cytokine expression point toward a tolerogenic
state of moDC that were exposed to GdA before acti-
vation. Two further assays added functional data to
this picture. Immature moDC are known to exhibit a
high degree of endopinocytotic activity that is lost
upon maturation leading toward an immunostimula-
tory phenotype.51 Immature DC, however, tran-
siently present incorporated antigen via MHC
molecules on their cell surface, yet do not express
costimulatory molecules. There is published data that
semi-mature DC, that have received maturation sig-
nals yet fail to downregulate endopinocytosis while
upregulating costimulatory molecules, exhibit tolero-
genic properties.11 When pretreating moDC with
GdA at least part of this endopinocytotic activity is
retained, again indicating toward a semi-mature
state and regulatory capacities. Furthermore, GdA-
pretreatment led toward a dose-dependent decrease
in T-cell stimulatory activity, the hallmark of immu-
nogenic DC. This finding is consistent with the find-
ing that isolated early pregnancy decidual myeloid
DC also showed a reduced T-cell stimulatory capa-
city.3 Our experimental setup does not allow proving
an antigen-specific tolerogenic behavior and may
not even be part of the physiological role of decidual
DC. Our data, however, do provide evidence that
DC lose their immunogenic, T-cell stimulatory capa-
city upon encounter of GdA that is part of the intri-
cate network of the feto-maternal interface.
Our data point toward a putative model in which
GdA that is endometrially secreted in high quanti-
ties during the first phase of pregnancy helps shape
the unique immunological interaction between
mother and fetus via DC-SIGN expressed on decid-
ual DC. This mechanism is mimicked by the unique
carbohydrate structure present on helminths like
S. manonii.
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Abstract
External cephalic version (ECV) at term is a safe proce-
dure and reduces the incidence of cesarean sections for
breech presentation. One of the known complications,
however, is an ECV-related disruption of the placental
barrier and a subsequent transfusion of fetal blood into
maternal circulation. While the incidence of ECV-related
fetomaternal hemorrhage (FMH) has been determined
recently in a large trial using a manual Kleihauer-Betke
test (KBT), questions remain on the amount of ECV-relat-
ed FMH. KBT, which detects fetal red blood cells (RBC)
on the basis of acidic resistance of fetal hemoglobin
(HbF), is known to be a sensitive test, yet prone to pro-
cedural errors limiting its accuracy in quantifying FMH. In
this study we investigated 50 patients for FMH before
and after ECV, using a dual-color flow cytometric test kit
with a lower limit of quantification of 0.05% fetal RBC in
maternal peripheral blood. Three patients had a quanti-
fiable increase of fetal RBC detected after ECV (0.06%;
0.08%; 0.1%). None of these subtle increments was pre-
dictable by ECV-related clinical parameters or translated
into fetal compromise. Using a sensitive and accurate
flow cytometric test method, our data provide further
assurance to mothers on the safety of ECV at term.
Keywords: Carbonic anhydrase; external cephalic ver-
sion; F-cells; fetomaternal hemorrhage; flow cytometry.
*Corresponding author:
Prof. Dr. Franz Kainer, MD
Department of Obstetrics and Gynecology
Ludwig-Maximilians University
Maistraße 11
80337 Munich
Germany
Tel.: q49-89-5160-4111
Fax: q49-89-5160-4516
E-mail: franz.kainer@med.uni-muenchen.de
Introduction
Planned cesarean sections have become the standard
mode of delivery for women with breech presentation
at term. To reduce the number of cesarean sections for
this indication, current evidence recommends external
cephalic version (ECV) as a safe procedure, which
improves the chance of cephalic birth given that the
appropriate selection criteria and safety measures are
applied w11x. Although there are solid data on its safety,
specific complications of ECV have been reported w5x.
Most notable among these complications is the disrup-
tion of the placental circulation-barrier, with ensuing feto-
maternal hemorrhage (FMH), commonly defined as a
transfusion of an equivalent of more than 30 mL fetal
blood into the maternal circulation. However, none of the
small studies or case reports addressing this issue had
the necessary statistical power to provide reliable data
on the incidence of FMH. Only recently has a cohort
study encompassing a total of 1311 women been pub-
lished; this work tested the amount of fetal cells in the
maternal circulation before and after ECV using a manual
Kleihauer-Betke test (KBT) w2x. In this well-powered trial,
3% of all patients had a positive KBT after ECV, with one
patient having an equivalent of more than 30 mL fetal
blood detectable in the maternal circulation. While pro-
viding solid data on the incidence of FMH in ECV, the
authors stress that the known limits of the KBT are of
concern w2, 17x. KBT, which differentiates fetal from
maternal red blood cells (RBC) based on the relative
resistance of RBCs containing hemoglobin F (HbF) to
acid elution, is inexpensive, but known to be prone to a
variety of procedural errors, making the quantification of
FMH difficult w8x. Flow cytometric test methods have
been evolving rapidly, and, by adding additional para-
meters to HbF, are able to control for HbF positive mater-
nal RBC (sF-cells) that are present in women with sickle
cell disease and thalassemia and in up to 25% of healthy
women in the second trimester of pregnancy w14, 17x.
Recently, Porra et al. evaluated a dual-color flow cyto-
metric test method that identifies F-cells by additionally
staining carbonic anhydrase (CA) w18x. As an inducible
enzyme in the respiratory chain, CA is only present in
adult RBCs, allowing for the specific quantification of
more than 0.05% fetal RBC in maternal blood when ana-
lyzing 2=106 RBCs. In the current study, we quantified
the number of fetal cells before and after ECV using this
dual-color flow cytometry test kit and correlated the
amount of FMH with ECV-related parameters.
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Figure 1 Clinical and sonographic parameters surveyed before external cephalic version (ECV) and procedure related risk-factors
documented after ECV.
Materials and methods
A total of 50 women were included in this prospective obser-
vational study of all singleton breech pregnancies during the
year 2007 that were subject to ECV in the department of obstet-
rics and gynecology Klinikum – Innenstadt of the Ludwig-Maxi-
milians University in Munich. All women gave their informed
consent, and the institutional Review Board approved the pro-
tocol. All women with breech presentation at term were evalu-
ated with a scoring system before ECV. We integrated data
regarding amniotic fluid index, fetal and placental position,
enlacement of the umbilical cord, estimated fetal weight, parity,
uterine tone and breech mobility (Figure 1). ECV was attempted
among women with a score of )8 points and was performed
according to the current German guideline on delivery in breech
presentation w10x. During an initial 30-min non-stress test, an i.v.
line was inserted and 5 mL of total venous blood were collected
into ethylenediaminetetraacetate (EDTA) anticoagulant. ECV was
performed by an experienced consultant and attempted nomore
than three times. After a post-ECV CTG of 30 min we collected
five additional mL of peripheral venous blood and labeled them
as ‘‘post ECV’’.
The procedure was documented with special reference to pre-
sumed risk factors for FMH: pressure on placenta, use of
tocolytic agent, failure of ECV, number of attempts, CTG decel-
erations and perceived pain (Figure 1).
Detection and quantification of fetal erythrocytes was per-
formed with the Fetal Cell Count Kit II (IQ-Products, Groningen,
The Netherlands). In brief, RBCs were washed three times in
phosphate-buffered saline (PAA-Laboratories, Pasching, Austria)
for 30 min in a formaldehyde-containing solution, washed once
more, and then permeabilized with sodium dodecyl sulfate
solution for 4 min at room temperature. RBCs were then stained
with a fluorescein isothiocyanate-labeled monoclonal mouse
anti-human fetal hemoglobin (HbF) antibody (recognizing the
HbF alpha-chain) and a phycoerythin-labeled polyclonal rabbit
anti-human CA antibody (recognizing the CA-II isoform). The
additional antibody for CA removed the need to determine HbF
threshold values, as it distinguished between the physiological
maternal F-cells (HbFq/CAq) and the genuine fetal RBCs (HbFq/
CA–). Prior to flow cytometry, optimal detector amplifications and
compensations were determined using unstained or single-
stained controls as well as cord-blood samples. Data acquisition
was performed on a FACSCalibur flow cytometer (Becton-Dick-
inson, Heidelberg, Germany). For quality control, spiking exper-
iments were performed using a mixture of peripheral blood of
nulliparous non-pregnant individuals and cord blood at various
dilutions. Concomitant test controls to validate and monitor the
quality of flow cytometric procedures were performed using
FetalTrol" test samples (IQ-Products, Groningen, The Nether-
lands). In concomitant test controls and spiking experiments, we
were able to confirm the level of quantification of 0.05% fetal
RBC when screening 2=106 maternal erythrocytes, as
described by Porra et al. (2007) w18x.
Data were acquired and analyzed using the Statistical Pack-
age for the Social Sciences (SPSS, Munich, Germany) software
version 15.0. Pre-ECV data as well as post-ECV data were
acquired in a dichotomous fashion and statistically analyzed
using the x2-test.
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Figure 2 Dot plot of the percentage of fetal hemoglobin (HbF)
positive/carbonic anhydrase (CA) negative red blood cells (RBC).
Every circle represents one patient and the results of two blood
samples drawn before and after external cephalic version (ECV).
Gray lines indicate "0.05% change, black line "0 change after
ECV.
Results
FMH volumes were evaluated for all 50 women with
breech presentation at term that opted for a trial of ECV,
both before and after the procedure. For technical rea-
sons, clinical pre-ECV data were not available for three
women, all of whom had -0.05% fetal RBC (HbFq/CA–)
before and after ECV. A percentage of fetal RBC of
0.05% defined the lower limit of quantification of our flow
cytometric test method. This was determined in 124
spiking experiments performed by Porra et al. and con-
firmed in our laboratory in five independent experiments
w18x. When screening 2=106 erythrocytes via flow cyto-
metry with this method out of 50 blood samples, 26 had
quantifiable amounts of fetal RBC before ECV, with
0.49% being the maximal percentage.
Whereas all of our blood samples contained equal or
greater amounts of fetal RBC after ECV, as compared to
before the procedure, only three procedure-related
increases were elevated above 0.05% (0.06%; 0.08%;
0.1%) (Figure 2). No procedure-related parameter pre-
dicted this event, and no fetal compromise was noted in
spite of an estimated FMH of 80 mL. In our study pop-
ulation, none of the five predefined procedure-related risk
factors or the eight parameters surveyed before ECV
(Figure 1) turned out to be an independent risk factor for
the small amount of FMH in the three cases with
)0.05% fetal RBC, as calculated by a x2-test.
Discussion
Several methods to quantify FMH are currently available
w15x. KBT is a time-honored method that is still used in
many laboratories, but has been shown to have a con-
siderable intra- and inter-test variability and to lack accu-
racy to quantify FMH, especially at concentrations of
-1% fetal cell in maternal peripheral blood w4, 8, 13x.
Furthermore, KBT is prone to overestimate FMH due to
the persistence of HbF, which is especially prominent in
patients with hemoglobinopathies, but is also present in
up to 25% of all healthy women in the second trimester
of pregnancy w14, 17x. Monoclonal fluorochrome-labeled
antibodies have been implemented, either in fluores-
cence microscopy or in flow cytometry, which has been
shown to be more sensitive compared to KBT w9x. Fluo-
rescence microscopy has been shown to be equally pre-
cise compared to flow cytometry – which remains the
gold standard for quantification of low concentrations of
FMH, but utilizes less expensive equipment w12, 15x.
Other techniques like the gel agglutination test (GAT)
have a role in determining an amount of fetal erythrocytes
in maternal circulation that exceeds the standard dose of
anti-D immune globulin administered in clinical practice
but are less suitable to detect low concentrations of FMH
w6x. In the same context, dual-color flow cytometry using
anti-HbF and anti-D monoclonal antibodies has been
recently evaluated to simultaneously D-type and assess
optimal doses of anti-D immunoglobulin in a single assay
w19x. In our experiment, we chose a test kit that uses anti-
HbF and anti-carbonic anhydrase Typ II (CA) antibodies
within an established and tested dual-color flow cyto-
metric approach to estimate as precisely and sensitively
as possible the low concentrations of fetal erythrocytes
expected in our study population w18x. Staining HbF, as
in our test method, instead of the D-antigen for discrim-
inating fetal erythrocytes, offers the advantage of being
applicable regardless of the blood group of the mother
or the fetus. A subpopulation of adult erythrocytes, how-
ever, contains HbF. These so-called F-cells are usually
discriminated by their slightly lower expression of HbF
compared to fetal erythrocytes. This somewhat arbitrary
cut-off level can be difficult to define, especially in cases
with large amounts of F cells w7x. To add specificity and
to circumvent the need for an arbitrary cut-off point, a
second monoclonal antibody was added to the test kit
used in our study, staining for CA, which is part of the
respiratory chain and is fully expressed only after birth
w1, 3x. In their study of 124 spiking experiments, Porra et
al. were able to confirm a lower level of quantification of
0.05%, which we were able to reproduce in concomitant
controls. With this test kit the percentage of women with
)0.05% fetal RBC even before ECV was higher than
previously reported w18x. Given that we confirmed our
level of quantification at 0.05% in preliminary experi-
ments as well as in concomitant controls, it is highly
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unlikely that any subtle alterations made by the manu-
facturer to improve the test kit might account for this dif-
ference. Since all of our controls confirmed that the test
method yielded accurate results, we must assume that
our study population happened to have physiologically
elevated levels of fetal RBC. There is some scientific
debate on how to estimate transfused fetal blood volume
from the percentage of fetal RBC in maternal circulation,
and where to draw the line between physiological values
and clinically relevant FMH w16x. For flow cytometric
analysis, 0.85% fetal RBC is considered to be equivalent
to 30 mL fetal whole blood, which is the volume com-
monly used to define clinically relevant FMH w16x. All of
the blood samples tested in this study were substantially
below this threshold before and after ECV. These data,
generated by screening 2=106 erythrocytes via flow
cytometry, were in line with the findings of Boucher et
al., who found a single FMH after ECV among 1311
women screened by single-slide manual KBT with
400=magnification w2x. Boucher et al. reported a total of
40 out of 1311 women as having an increase in RBC
volume after ECV. Given the large study population, their
data are likely to represent the true incidence of FMH
after ECV. Our cytometry data provide further assurance
about the safety of ECV, given that quantifiable percent-
ages of fetal RBCs were only found in three of 50 women,
even in a population with rather high physiologic levels
of fetal RBC before ECV and with a highly precise test
method. Blood samples of these three women barely
crossed the lower limits of quantification.
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nist RU486 (mifepristone) was accomplished by an upregula-
tion of PR-A expression in our study. We conclude that gesta-
genic effects on HUVECs independent of modulators are 
mediated via the PR-A.  Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Vascular endothelial cells are involved in the regula-
tion of angiogenesis, inflammatory responses, vascular 
tone and permeability. Impaired endothelial function 
leads to increased cardiovascular risk  [1] . In females, en-
dothelial dysfunction gradually ensues after the meno-
pause  [2] , and is associated with disturbed dilatation  [3] , 
decline in endothelial nitric oxide synthase (eNOS) activ-
ity and nitric oxide (NO) bioavailability as well as abnor-
mal endothelial morphology  [4, 5] . These functional al-
terations of endothelial cells contribute to the increased 
risk of cardiovascular diseases seen in postmenopaus-
al women  [6] . The incidence of coronary heart disease 
(CHD) in premenopausal women is significantly lower 
 Key Words 
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 Abstract 
 Effects of female steroid hormones on endothelial cells are 
gaining increased importance due to several studies on the 
effects of hormonal treatment on cardiovascular risk. Recent 
data argue for an improvement of endothelium-derived
relaxation and impaired vascular contraction by estradiol, 
whereas progesterone and testosterone might entail con-
trary effects. So far, gestagenic influence on endothelial cell 
physiology is poorly understood. Human umbilical vein en-
dothelial cells (HUVECs) exposed to the female sex hormones 
estradiol and progesterone show expression of estrogen
receptor- ! (ER ! ) and progesterone receptor A (PR-A), and 
are negative for ER " and PR-B. The aim of this study was to 
analyze the expression and stimulation of PR-A and -B in
HUVECs after stimulation with progesterone and PR antago-
nists that are commercially available. PR-B expression or up-
regulation was abrogated after application of progesterone 
or antagonists to HUVECs. Expression of PR-A could be sig-
nificantly upregulated with progesterone and mifepristone. 
Unexpectedly, stimulation with the progesterone antago-
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than in age-matched men with similar risk profiles and 
increases after menopause  [7–9] .
 With regard to hormonal treatment (HT) in post-
menopausal women, progesterone is generally co-admin-
istered with estrogen to prevent endometrial cancer by 
opposing the proliferative effect of estrogens. So far, the 
influence of the administered progestagens on cardiovas-
cular function and development of atherosclerosis re-
mains controversial  [10, 11] . However, HT has been re-
garded as an effective tool to protect postmenopausal 
women from CHD  [12] . Until now, major randomized 
clinical trials have failed to confirm the cardiovascular 
advantages of HT  [13] .
 The Heart and Estrogen/Progestin Replacement Study 
showed that the co-administration of medroxyprogester-
one acetate (MPA) with conjugated equine estrogen (CEE) 
did not reduce the rate of events in postmenopausal wom-
en with established CHD, yet the treatment did increase 
the rate of thromboembolic events and gallbladder dis-
ease  [14–18] .
 The Women’s Health Initiative trial showed that HT 
combined with CEE and MPA was associated with a non-
significant increase in CHD in postmenopausal women, 
whereas women in the sister cohort, receiving CEE alone, 
showed a nonsignificant decrease in coronary events, 
along with a significant reduction in a composite out-
come of CHD events in younger women  [19, 20] .
 However, progesterone or other synthetic progestins 
have variable influences on endothelial function. For ex-
ample, natural progesterone increases endothelial NO 
production, whereas MPA is devoid of such action  [21] . In 
nonhuman primates, MPA has been shown to interfere 
with the atheroprotective effects of estrogens, which was 
not encountered with natural progesterone  [22, 23] . In 
support of these observations, discrepant effects of pro-
gestins have also been described in other tissues  [24] .
 A diversity of progesterone receptor (PR) activators 
and inhibitors exists with different potential to bind to 
PR-A, PR-B or both. In our study, we analyzed the expres-
sion of PR-A and PR-B in human umbilical vein endothe-
lial cells (HUVECs) after stimulation with progesterone 
and its antagonist mifepristone with specific monoclonal 
antibodies by immunocytochemistry. 
 Material and Methods 
 Cell Culture 
 HUVECs were obtained from Promocell (Heidelberg, Germa-
ny) at passage 2 or 3. The cells were cultivated in phenol red free 
endothelial cell growth medium (ECGM) (Customer formula-
tion, Promocell, Heidelberg, Germany). ECGM contained 10% 
fetal bovine serum, 1.0 mg/ml hydrocortisone, 0.1 ng/ml endo-
thelial growth factor, 1.0 ng/ml basic fibroblast growth factor and 
2 ml endothelial cell growth substrate as well as 5 ml streptomycin 
(Biochrom AG, Berlin, Germany) and 5 ml amphotericin B (Bio-
chrom) in 500 ml medium. 
 HUVECs were used for experiments between passages 3 and 4. 
All cell cultures were maintained in a humidified 5% CO 2 atmo-
sphere at 37 ° C. HUVECs were incubated with progesterone and 
mifepristone in different concentrations (0–100 nmol/ml;
 table 1 ) and cultivated for up to 72 h on chamber slides (Nunc, 
 Wiesbaden, Germany). These concentrations are related to physio-
logical progesterone concentrations in pregnant human females. 
Cells were fixed with methanol/ethanol (50/50%; Merck, Darm-
stadt, Germany). The Human Investigation Review Board of the 
Ludwig Maximilian University Munich approved the study.
 Immunocytochemistry 
 Expression of PR-A was analyzed by using a specific monoclo-
nal antibody (1A6, Mouse IgG1, 1: 50, Immunotech, Prague, Czech 
Republic) and the ABC staining method (Vectastain Elite mouse-
IgG-Kit, Vector, Burlingame, Calif., USA). Staining intensity was 
graded by using a semiquantitative score by counting the absolute 
percentage of positive-stained cells. 
 Two blinded, independent observers evaluated the specific 
immunocytochemical staining reaction without knowing the pri-
or evaluation of each specimen. In each condition, 6–9 indepen-
dent specimens were taken and evaluated independently.
 In brief, HUVECs were cultivated under sterile conditions in 
chamber slide cultures Quadriperm (Nunc) for up to 72 h, dried, 
wrapped and stored at –80 ° C as described earlier  [25] . After 
thawing, cells were briefly fixed with formalin (Merck; 5% in 
PBS, 5 min). Slides were incubated in methanol/H 2 O 2 (30 min) 
to inhibit endogenous peroxidase activity, washed in PBS
(5 min) and treated with goat serum (20 min, room temperature, 
RT) to reduce nonspecific background staining. Incubation 
with the primary anti-PR-A antibody (1A6, Mouse IgG1, 1: 50, 
Immunotech) was done overnight at 4 ° C. Sections were then 
incubated with the biotinylated secondary anti-mouse antibody 
(1 h, RT) and avidin-biotinylated peroxidase (45 min, RT). Be-
tween each step, the sections were washed with PBS (pH 7.4), 
three times. Peroxidase staining reaction was done with diami-
nobenzidine/H 2 O 2  (1 mg/ml; 5 min) and stopped in tap water 
(10 min). Sections were counterstained in hematoxylin (1 min) 
and then coverslipped. In controls, the primary antibody was 
replaced with preimmune mouse serum. Positive (MCF-7 breast 
cancer cell line) and negative control cells (MDA-MB231), both 
from American Type Culture Collection (Manassas, Va., USA), 
for PR-A staining were always included. The slides were finally 
Table 1. Substances used for stimulation of PR-A
Substance Dilution Source
Progesterone, nmol/ml 0.1–100 Sigma-Aldrich
Mifepristone, nmol/ml 0.1–100 Roussel–Uclaf
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embedded in mounting buffer and examined with a Zeiss Axio-
phot photomicroscope (Carl Zeiss, Jena, Germany). The extent 
of PR expression was determined in a blinded fashion in one run 
with identical staff, equipment, and chemicals. 
 From each section, 5 digital pictures were taken at random of 
different places of stained HUVECs ( ! 200 magnification; 3CCD 
color camera; Axiocam) and examined with a Zeiss Axiophot 
photomicroscope. 
 Statistics 
 The SPSS/PC software package (SPSS, Chicago, Ill., USA) ver-
sion 15.0 and 16.0 was used for collection, processing, and statis-
tical data analysis. Statistical analysis was performed using the 
nonparametric Mann-Whitney U signed rank test for compari-
son of the means. p  ! 0.05 values were considered statistically 
significant.
 Results 
 Progesterone 
 Progesterone acts as a natural PR ligand (PR-A, PR-B). 
HUVECs stimulated with 100 pmol/ml and 1, 10, and 100 
nmol/ml progesterone, respectively, showed expression 
of PR-A after cultivation for up to 72 h ( fig. 1 a–e). Sig-
nificantly elevated PR-A expression could be observed by 
administration of 10 and 100 nmol/ml progesterone, as 
described (p  ! 0.05;  fig. 1 f).
 Mifepristone 
 Unexpectedly, administration of the PR antagonist 
RU486 led to an upregulation of PR-A expression.
HUVECs stimulated with 1, 10, and 100 nmol/ml mife-
pristone showed significant upregulation of PR-A in all 
cases compared with nonstimulated controls (p  ! 0.05, 
respectively;  fig. 2 ). 
 Discussion 
 Recently, basic findings on the expression of estrogen 
receptor (ER) and PR in HUVECs were published, indi-
cating the lack of ER " and PR-B expression in HUVECs 
 [25] .
 In our study, we were able to demonstrate that proges-
terone acts as an activator on endothelial cells and is able 
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 Fig. 1.  a PR-A expression in unstimulated HUVECs.  ! 10.  b PR-A 
expression in HUVECs after 0.1 nmol/ml stimulation with pro-
gesterone.  ! 10.  c PR-A expression in HUVECs after 1.0 nmol/
ml stimulation with progesterone.  ! 10.  d PR-A expression in 
HUVECs after 10 nmol/ml stimulation with progesterone.  ! 10. 
 e PR-A expression in HUVECs after 100 nmol/ml stimulation 
with progesterone.  ! 10.  f PR-A expression in HUVECs after in-
cubation with progesterone. 
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to upregulate PR-A expression in a dose-dependent man-
ner. In contrast to former studies, PR antagonist RU486 
also led to an upregulation of PR-A expression.
 The cellular effects of gestagens are mediated by bind-
ing to nuclear receptors (PR) which activate transcription 
of genes involved in cellular growth control. So far, endo-
thelial effects of gestagens are poorly understood and, as 
compared with data on estrogenic influences on endo-
thelial cells, also poorly investigated. Fu et al. [26] inves-
tigated effects of progesterone and MPA on actin remod-
eling, moesin activation and cell movement in human 
endothelial cells. They were able to show that both gesta-
gens regulate endothelial cell movement by rapidly sig-
naling to the actin-binding protein moesin and to the 
actin cytoskeleton. 
 To further study the effects of gestagens on vascular 
function, Hermenegildo et al. [27] studied the effects of 
progesterone and MPA on prostacyclin production in 
HUVECs. Both gestagens significantly increased prosta-
cyclin release in a time- and dose-dependent manner by 
enhancing Cox-1 and Cox-2 expression and activities.
 In contrast to our recent findings on the lack of PR-B 
expression on HUVECs, Tatsumi et al. [28] described PR-
A and PR-B mRNA expression on HUVECs. The authors 
investigated the effect of progesterone, MPA, norethin-
drone acetate, levonorgestrel as well as dienogest on cy-
tokine-stimulated HUVEC expression of adhesion mol-
ecules. However, progesterone or dienogest did not af-
fect IL-1 ! -stimulated ICAM-1 or VCAM-1 expression, 
whereas the other gestagens did.
 Additionally, concomitant addition of mifepristone 
blocked the gestagen-induced increase in adhesion mol-
ecules. They concluded that dienogest unlike other syn-
thetic progestins lacks the stimulatory effect on cell adhe-
sion molecules  [28] . We were able to show that HUVEC 
stimulation with increasing amounts of RU486 leads to 
an upregulation of PR-A in a dose-dependent manner. 
Our data implicate that RU486 only acts as a PR antago-
nist in the presence of PR activators like progestone. 
 The Women’s Health Initiative trial reported an excess 
of heart diseases in postmenopausal women receiving 
MPA. Therefore, Simoncini et al. [21] investigated the ef-
fects of progesterone, MPA, dydrogesterone and its me-
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 Fig. 2.  a PR-A expression in unstimulated HUVECs.  ! 10.  b PR-A 
expression in HUVECs after 0.1 nmol/ml stimulation with mife-
pristone.  ! 10.  c PR-A expression in HUVECs after 1.0 nmol/
ml stimulation with mifepristone.  ! 10.  d PR-A expression in 
HUVECs after 10 nmol/ml stimulation with mifepristone.  ! 10. 
 e PR-A expression in HUVECs after 100 nmol/ml stimulation 
with mifepristone.  ! 10.  f PR-A expression in HUVECs after in-
cubation with mifepristone. 
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tabolite 20-a-dihydrogesterone on endothelial synthesis 
of NO, and characterized the signaling events recruited 
by these compounds. In contrast to dydrogesterone, pro-
gesterone and 20-a-dihydrogesterone, MPA did not trig-
ger eNOS enzymatic activation and decreased the extent 
of eNOS induction by estradiol. The authors concluded 
that their findings support the concept that synthetic 
progestins act differently on vascular cells and that hor-
monal preparations may differ in their cardiovascular ef-
fects  [29] .
 Studies on the effects of HT in postmenopausal wom-
en indicate procoagulant effects of gestagens and estro-
gens. To further study the effects of gestagens on hemo-
stasis, Zerr-Fouineau et al. [30] investigated whether pro-
gestins affect the formation of NO in endothelial cells 
and examined the underlying mechanism. 
 Certain progestins, including MPA, reduced the anti-
aggregatory effect of endothelial cells by decreasing the 
expression of eNOS and the formation of NO in endothe-
lial cells; an effect that is mediated via activation of glu-
cocorticoid receptors.
 In summary, our study showed that progesterone is 
able to upregulate PR-A expression in a dose-dependent 
manner and that the PR antagonist mifepristone also acts 
as a PR activator when administered solely.
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Summary. Glycodelin (Gd), previously known as
placental protein 14 (PP 14), acts as an immuno-
suppressive glycoprotein by suppressing the cytolytic
capacity of human natural killer (NK) cells and T-cells in
vitro. Glycodelin is expressed in normal glandular
epithelium of the endometrium as well as in normal and
malignant glandular cells in and outside of the
reproductive tract. Recently, Gd expression was
demonstrated in normal and cancerous human breast
tissue. 
Paraffin-embedded breast cancer tissue blocks
(n=121) were examined for Gd expression. No part of
the specimens contained carcinoma in situ.
Gd expression was present in lobular and ductal
breast carcinoma. We observed expression of Gd in
breast cancer independent of grading. With regard to
nodal status, no significant differences in the expression
of Gd between cancer tissue from patients with or
without axillary lymph node metastases were present.
However, Gd expression was found to be significantly
higher in breast cancer tissue when the staining reaction
for steroid receptors was also positive. 
These results implicate that Gd might be an
additional marker for the differentiation of breast cancer
tissue. To which extent Gd could serve as an additional
indicator for breast cancer survival is part of our ongoing
research.
Key words: Glycodelin, Breast cancer, Differentiation,
Immunhistochemistry
Introduction
Breast cancer is the most common malignant tumour
in women worldwide. Due to constantly enhanced
therapeutic regimens its survival rates have improved
substantially over the last 20 years. Hormone sensitivity
is the most important predictive marker, indicating better
prognosis due to available endocrine treatment options.
In addition, hormone receptor positivity in breast cancer
cells indicates better differentiation and less aggressive
malignant behaviour. Treatment of early stage breast
cancer depends on endocrine responsiveness, which is
defined as staining steroid-receptor positive in more than
10% of breast cancer cells (Goldhirsch et al., 2007). 
However, the biological significance of low-level
expression of steroid receptors in breast cancer cells
remains an area of scientific concern (Payne et al.,
2008). Additional markers that are associated with better
differentiation and intracellular signalling are needed in
order to tailor endocrine therapy to those cancer patients
that are likely to respond. The immunoreactivity of
glycodelin (Gd) was evaluated in invasive breast cancer
specimens (n=121) to investigate the capability of Gd as
a marker of differentiation.
Glycodelin, a member of the family of lipocalins, is
a secreted glycoprotein found in variable concentrations
and tissue specific glycosylation in the human genital
tract and is known to be expressed in breast cancer
(Kamarainen et al., 1999). It exists in various isoforms
with different glycosylation patterns that influence their
staining behaviour (Morris et al., 1996; Tse et al., 2002;
Chiu et al., 2007). The structure of a specific breast
cancer glycodorm remains to be investigated.
Nevertheless, invasive breast carcinoma without axillary
or distant metastases were found to have a higher
expression of Gd, hinting towards a better differentiation
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and prognosis (Jeschke et al., 2005). Kämäräinen et al.
(Kamarainen et al., 1997) were able to show that
glycodelin expressing cells also upregulated markers of
organized epithelia, such as cytokeratins 8 and 18, as
well as E-cadherin, and physiologic changes in
intracellular distribution of ß-catenin. This expression-
pattern was accompanied by the acquisition of a
phenotype of organized glandular epithelium. 
Gd is further known to have direct immuno-
modulatory effects by suppressing the reactivity of
stimulated T- lymphocytes and by inhibiting NK- and B-
cell function in vitro (Seppala et al., 2002). Therefore,
Gd might contribute towards tumour progression in an
early phase of carcinogenesis in which organized local
immune evasion is provided by the expression of Gd,
while intracellular signalling is still intact.
Material and methods
Specimens
Formalin-fixed paraffin-embedded tissue from breast
cancer patients undergoing surgery at the First
Department of Obstetrics and Gynaecology of the
Ludwig- Maximilians-University of Munich were
investigated. All specimens had a histological
classification as lobular or ductal breast cancer by a
gynaecological pathologist. Patients with metastatic
disease were excluded, as well as all patients with any
proportion of ductal carcinoma in situ (DCIS) within
tumorous tissue, as Gd expression has been seen in
virtually all cases of DCIS (Jeschke et al., 2005). 
Tissue blocks of 121 breast cancers fulfilled the
above mentioned criteria. The mean age of the patients
was 62,2 (SD 9,8) years (45-84 years) with 85% being
postmenopausal. Out of the 83 ductal carcinoma 9 were
graded as “G1”, 40 as “G2” and 34 specimens as “G3”.
With regard to lobular carcinoma (n=38) 15 were graded
as “G1”, 16 as “G2”, 3 as “G3”. Grading was performed
according to criteria published by Elston and Ellis
(Elston and Ellis, 2002). If one or more of the criteria
was not assessable due to technical variations the
specimen was classified as Gx, as was the case in 4
lobular carcinoma specimens. Nodal involvement, as
well as hormone receptor status was equally distributed
among the study population. As part of the clinical
work-up ER-α and PR-A isoforms are evaluated. In our
study population all “receptor-positive” breast cancer
specimens were positive for ER-α and PR-A. (ER-α and
PR-A positive: 48 ductal, 20 lobular; ER-α and PR-A
negative: 35 ductal, 18 lobular).
Immunohistochemistry 
Immunohistochemical detection of Gd expression on
paraffin sections (4 µm) of breast cancer tissue was
performed according to procedures described previously
(Jeschke et al., 2005). In a first step sections were
incubated in 3% methanol/ H2O2 (30 min) to inhibit
endogenous peroxidase activity, washed in phosphate-
buffered saline (PBS, pH 7.4) for 5 min and treated with
1.5% goat serum for 20 min at 22°C to reduce non-
specific background staining. To loosen aldehyde bonds
sections were boiled in an acidic buffer (pH6.0)
containing 2% Na-citrate and citric acid for 5 min and
subsequently cautiously cooled to room temperature in
tap water. The primary monoclonal antibody, known to
recognize the CH epitope on Gd was purchased at
Glycotope GmbH (Berlin, Germany) (code: A87-B/D2;
isotype: IgG1κ) has been characterized previously(Jeschke et al., 2006). Specific binding of the antibody to
Gd was analyzed by Western blot analysis. To specify
immunoreactivity against the A isoform of glycodlin we
included a seminal vesicle (known to express glycodlein
S, which is the other most common Gd isoform) as a
negative control (Fig. 1C). Incubation with the primary
antibody was performed overnight at 4°C. Sections were
then incubated with biotinylated secondary anti-mouse
antibody (1:200) for 1 hr and then with avidin-biotin
peroxidase complex (1:25) (ABC) prepared according to
manufacturer’s instructions for 45 min (Vectastain-Elite-
ABC Kit, Vector Laboratories, Burlingame CA, USA).
Labelling was revealed by incubation with 1 mg/ml
diaminobenzidine/H2O2 (Dako, Hamburg, Germany) for5 min and the reaction stopped by washing in tapwater
for 10 min. Sections were counter-stained in hemalaun
for 1 min, then cover-slipped. The primary antibody was
replaced with pre-immune rabbit serum in controls.
Positive (decidual tissue) and negative (human
trophoblast tissue) controls were always included.
Two independent observers, including a
gynaecological pathologist, assessed the specimens
using the semi-quantitative immunoreactive score (IRS)
after Remmele and Stegner - routinely used for assessing
receptor positivity in breast cancer - evaluated the
intensity and distribution patterns of the staining
reaction. The IRS was calculated by multiplication of
optical staining intensity (graded as 0=no, 1=weak,
2=moderate and 3=strong staining) and the percentage of
positive stained cells (0=no staining, 1≤ 10% of the
cells, 2=11-50% of the cells, 3=51-80% of the cells and
4≥ 81% of the cells). Evaluation of each specimen was
performed without having any knowledge of the
pathological diagnosis. For all sections, we assessed the
mean optical density and the quantity of pixels which
had a positive reaction for glycodelin using the KSRun
software (imaging system KS400, release 3.0; Zeiss,
Vision GmbH, Germany)
Statistics
The SPSS/PC software package, version 16.0 (SPSS
GmbH, Munich, Germany), was used for collection,
processing and statistical analysis of all data. Statistical
analysis was performed using the non-parametrical
Mann-Whitney U test and in case of 3 or more groups its
extension, the Kruskal-Wallis one-way analysis of
variance by ranks. All p-values resulted from two-sided
statistical tests and p≤ 0.05 was considered to be
significant.
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Results
Characteristics of study population
121 breast cancer specimens were included in the
study. 83 of them were classified as ductal carcinoma, 38
as lobular. Within those subgroups grading was
distributed as follows: 89% (n=74) of ductal carcinoma
were classified being G2 or G3, whereas for lobular
carcinoma 81% (n=38) were graded as G1 or G2 (Table
1). 
Glycodelin expression 
Gd was expressed both in lobular and in ductal
breast carcinoma. Although there was a tendency
towards increased staining in ductal carcinoma, no
significant differences were found (median IRS for
ductal carcinoma: 1.81 versus median IRS = 1.55 lobular
carcinoma) (Fig. 1A). Gd expression in lobular and
ductal carcinoma cells was independent of their grading
(Fig. 1B). Fig. 2C shows staining examples of a Gd
negative (IRS:0) lobular G1 breast cancer specimen and
a Gd positive (IRS:4) ductal G2 specimen. Although not
statistically significant, there has been a tendency
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Fig. 1. Glycodelin is equally expressed in ductal and lobular breast cancer and its expression is independent from grading. Immunohistochemical
evaluation according to the Immune Reactivity Score (IRS) revealed no significant difference between ductal and lobular breast cancer specimens (A).
Two staining examples and a negative control (seminal vesicle) are shown in (C). For box plots boxes indicate 25th and 75th Quartile with horizontal
bars indicating median staining intensity. Error bars denote standard error of mean (SEM) (A, B, D). No statistically significant difference between
different grading characteristics could be determined for ductal and lobular breast cancer (B). Summative results revealed a tendency towards higher
expression in G2 tumours yet no statistically significant difference (C). Bars: 200 µm. 
Table 1.
ductal lobular
G1 9 15
G2 40 16
G3 34 3
Gx 0 4
Σ 83 38
                       
towards higher expression of Gd in G2 tumours in a
pooled analysis of lobular and ductal carcinoma (Fig.
1D)
There was no significant difference between tumours
of patients with positive axillary lymph nodes and those
without. Median IRS for tumours without nodal
involvement was 1.59 (n=61) for those with affected
lymph nodes 1.87 (n=60) (Fig. 2). 
Gd expression was found to be significantly higher
in those specimens that also stained positive for steroid
receptors. Median IRS of all hormone receptor negative
tissue sections was 1.4 (n=53) compared to hormone
receptor positive specimens that had a median IRS of
1.99 (n=68) (p=0.033).
Discussion
Gd expression was analysed in breast cancer tissue
without any parts of the specimens containing carcinoma
in situ. The monoclonal antibody used in these
experiments detects specific carbohydrate structures of
Gd (Jeschke et al., 2006). Glycosylation seems to play a
pivotal functional role in Gd (Seppala et al., 2007). We
found a significant increase in glycosylated Gd protein
expression in hormone receptor positive (ER-α and PR-
A) specimens. However, Gd expression was independent
of nodal involvement, grading and cancer type. To our
knowledge this study is the largest done so far on Gd
expression in breast cancer. Kämärrainen et al. (1999)
were able to describe Gd expression in 21/35 ductal
carcinomas, 9/9 tubular carcinomas, 9/9 mucinous
carcinomas, 3/3 mixed ductal/tubular carcinomas and
7/11 lobular carcinomas However, no differentiation was
made according to ductal carcinoma in situ (DCIS).
Later on, it became clear that DCIS uniformly stained
positive for Gd (Jeschke et al., 2005). Therefore, we
excluded all specimens that contained any fraction of
DCIS in addition to invasive cancer. In accordance to the
study population used by Kämärrainen et al. we did not
find any correlation of Gd expression and nodal
involvement (Kamarainen et al., 1999). The pivotal
clinical marker of differentiation is “Grading”. Grading
of our specimens was performed by a gynaecological
pathologist according to the most commonly used
international criteria by Elston and Ellis (Elston and
Ellis, 2002). To our knowledge the influence of grading
on Gd expression has never been tested before. 
Surprisingly, no significant differences between
grading types was seen. A tendency towards higher
levels of Gd expression in G2 tumours only in a pooled
analysis might be explained by the immunomodulatory
properties of Gd. Antigenic properties of tumours are
altered during carcinogenesis. Secretion of a
glycoprotein that inhibits NK- and T-cell responses
locally would be more important for earlier tumour stage
survival. We speculate that in later stages of
differentiation this mechanism becomes less important.
Nevertheless, the tendency of G2 tumours to express Gd
did not reach statistical significance in our study
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Fig. 3. Glycodelin expression in breast cancer was significantly higher in
tissue specimens that are receptor positive as compared to receptor
negative specimens (p<0,05). Receptor negative specimens (n=53)
were compared to receptor positive specimens (n=68) and statististical
significance of histochemical reactivity against Gd was determined by
the Mann-Whitney-U test.
Fig. 2. Glycodelin expression of breast cancer dependent on nodal
status. Patients with positive axillary lymph nodes showed no
significantly higher Gd expression.
             
population.
Gd expression was found to be significantly higher
in those specimens that were positive for steroid
receptors. Expression of Gd is known to be dependent on
steroid hormone levels. It is normally expressed in
steroid responsive tissues of the reproductive tract and
its secretion is strictly dependent on progesterone levels
(Seppala et al., 2002). In endometrium, as well as
cancerous tissue, Gd expression changes with steroid
receptor notably PR expression (Mandelin et al., 2003;
Stavreus-Evers et al., 2006). In our study population all
68 „receptor-positive“ invasive breast cancer specimens
stained postive for ER-α and PR-A in the routine clinical
work-up. IN routine clinical work-up other isoforms are
usually not assessed as ER-α and PR-A positivity will
decide whether to start antihormonal therapy. Possible
associations between Gd and other steroid receptor
isoforms, as well as putative Gd isoform differences
between tissue specimens could not be investigated in
this study. Gd is known to be an efficient inhibitor of E-
selectin mediated cell adhesion in vitro, fostering tumour
spread (Jeschke et al., 2003). Its high expression in well-
differentiated breast cancer tissue might contribute
towards the clinical phenomenon of early micro-
metastatic spread even in small G1 tumours. On the
other hand, Gd expression is known to be associated
with higher differentiation. During neoplastic
progression Gd mRNA and protein levels fall, while
transfection of glycodelin cDNA in breast cancer cell
cultures suppressed proliferation and induced a
differentiated epithelial glandular phenotype (Jeschke et
al., 2003, Kamarainen et al., 1997). Taken together, our
study promotes Gd as an additional marker for
differentiation, though additional, larger studies, as well
as carefully designed in vitro experiments, will be
needed to show progesterone dependent differentiation
and glycosylation effects on breast cancer.
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Ovarian Cancer-derived Glycodelin Impairs In Vitro
Dendritic Cell Maturation
Christoph Scholz,* Elisabeth Rampf,* Bettina Toth,w Regina Brunnhuber,*
Tobias Weissenbacher,* Klaus Friese,*w and Udo Jeschke*
Summary: Local immunosuppressive mechanisms shape the
tumor microenvironment and contribute to carcinogenesis. In
ovarian cancer such mechanisms have been shown to influence
survival. Dendritic cells (DCs) are central immunity regulators and
induce potent cytotoxic T-cell responses as well as peripheral
tolerance depending on modulatory stimuli. Here, we show that
ovarian cancer-derived glycodelin (Gd), a glycoprotein that
physiologically modulates local immunity in early pregnancy,
induces a tolerogenic DC phenotype. Gd was isolated with high
performance liquid chromatography from the malignant ascites
of ovarian cancer patients. DCs were generated from monocytes
of healthy donors and exposed to Gd with or without an inflam-
matory stimulus (tumor necrosis factor-a and interleukin 1-b). We
investigated the effect of Gd on DC surface marker expression,
endopinocytotic activity, cytokine profile, and lymphoproliferative
activity. DCs that were exposed to Gd altered their phenotype as
seen by a differential expression of costimulatory molecules,
whereas expression of DC-specific intercellular adhesion molecule
3-grabbing nonintegrin, a marker of an immature phenotype, was
increased. Functional data provided further evidence for the
immature/tolerogenic properties of Gd-pretreated DCs. Antigen
uptake was retained, production of interleukin-10 was increased,
and lymphoproliferative activity was reduced. This effect was
reversible by adding Gd-blocking antibodies. Gd, which is found
in the malignant ascites of ovarian cancer patients, induces a
tolerogenic phenotype in DC, thereby shaping an immunodeficient
tumor micromilieu.
Key Words: dendritic cells, glycodelin, pregnancy glycoproteins,
tumor micromilieu, epithelial ovarian cancer
(J Immunother 2009;00:000–000)
Human tumors employ many strategies to evade orstructure host immune responses to shape a micro-
environment that supports their malignant growth.1 As
such, one of the dominant mechanisms of immune evasion
is tumor antigen-specific T-cell tolerance. Dendritic cells
(DCs) are central immunity regulators that can either
initiate primary T-cell immune responses or maintain
peripheral tolerance by suppressing (auto) antigen-specific
immunity.2 In ovarian cancer, immunocompetent DC
infiltration has been associated with prolonged survival,
whereas immunosuppressive mechanisms are associated
with disease progression and increased mortality.3,4
Furthermore, immunogenicity toward ovarian cancer anti-
gens has been improved by suppressing DC-mediated
tolerogenic mechanisms.5 The capacity of DCs to induce
immunity versus tolerance is dependent on their state of
activation, which, in turn, is influenced by exogenous
factors that are present during antigen encounter.6 ‘‘Danger
signals’’ [proinflammatory cytokines such as tumor necrosis
factor-a (TNF-a) and interleukin 1-b (IL 1b)] trigger DC
maturation and subsequent antigen-specific immune re-
sponses.7 DCs are employed in immunotherapy protocols
against various malignancies, including ovarian cancer,
because of their unrivaled capacity to initiate cytotoxic
T-cell responses.8 Other, noninflammatory signals, how-
ever, lead toward a tolerogenic DC phenotype that might
be detrimental to an antitumor immune response.
Glycoproteins are part of the tumor-specific array of
immunosuppressive mediators. Glycodelin (Gd), a member
of the lipocalin family, is a secreted glycoprotein found in
the human genital tract. Its known physiologic function is
in localized immunosuppression during early pregnancy. It
is secreted in high quantities by the uterine mucosa to allow
the semiallogeneic blastocyst to implant into the endo-
metrium.9 In ovarian cancer, Gd expression is associated
with dedifferentiation, angiogenesis, and reduced survi-
val.10,11 It is currently used as a biomarker for early
detection and monitoring of recurrent ovarian cancer.12
Immunomodulatory Gd effects are known for many
effector cells of the innate and adaptive immune system. Gd
directly inhibits natural killer-cell and T-cell function,
suppressing interferon-g, and fostering IL-5 and IL-4
secretion.13–15 Monocytes express a Gd receptor and we
were able to show recently that Gd derived from human
pregnancy induces a tolerogenic phenotype in DC.16,17
However, immunologic effects of cancer-derived Gd on
DCs—as the central regulators of antitumor immunity—
have not been tested so far.
To examine the immunomodulatory properties of
ovarian cancer-derived Gd, we investigated the effect of
Gd, isolated from malignant ascites, on the phenotype and
functionality of monocyte-derived DCs in vitro.
MATERIALS AND METHODS
Cell Culture
Cell cultures were maintained in Roswell Park
Memorial Institute 1640 (Biochrom, Berlin, Germany)Copyright r 2009 by Lippincott Williams & Wilkins
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supplemented with 2% heat-inactivated human pooled
AB serum (BioWhittaker, Walkersville, MD), 2mM
L-glutamine (Life Technologies, Paisley, UK), 50U/mL
penicillin, and 50mg/mL streptomycin (both from Sigma,
Munich, Germany); hereafter, this supplemented medium is
referred to as complete medium. All cultures were main-
tained at 371C, 5% CO2, and 95% humidity.
Isolation and Culture of Human DCs
DCs were generated from peripheral blood monocytes
(PBMCs) as described.18 PBMCs were isolated from
healthy donors by Ficoll density-gradient centrifugation
(Biochrom, Berlin, Germany), washed 3 times, and
resuspended in complete medium. For 60 minutes, PBMCs
(5 106/mL) were allowed to adhere in 75-cm2 culture
flasks. Nonadherent cells were removed by vigorous
pipetting. After overnight incubation, cells were transferred
into 6-well plates (1.5 106 cells/2mL) with fresh complete
medium supplemented with 1000 IU/mL granulocyte
macrophage colony-stimulating factor (Leukine; Immunex,
Seattle) and 500 IU/mL (IL-4 Promega, Madison). An
aliquot of DCs was assessed for purity before further use.
DC maturation was induced using TNF-a(1000U/mL)
(R&D Systems, Wiesbaden, Germany) and IL-1b (10ng/mL)
(Strathmann Biotech, Hannover, Germany).
Gd Purification
The Gd used in this study was purified from pooled
human ovarian cancer ascites as previously described.19,20
Ovarian cancer ascites was loaded onto a diethylaminoethyl
sepharose column and fractionated on a 50 to 500mM
NH4HCO3 gradient followed by gel filtration and a second
anion exchange chromatography step on Resource Q. Final
purification was obtained by hydrophobic interaction
chromatography on Octyl-Sepharose and Resource-Phe
(all columns: GE Healthcare, Freiburg, Germany)
(Fig. 1A). To further determine purity, isolated protein
batches were silver stained as described previously.21
Briefly, protein batches were loaded on polyacrylamide
gels and sodium dodecyl sulfate polyacrylamide gel
electrophoresis was performed. After that the gel was fixed
for 30 minutes in methanol/acetic and incubated in 10%
glutaraldehyde for 30 minutes. After a washing step in
deionized water, the gel was stained in silver nitrate solution
for 15 minutes. After another washing step, developing
solution was added and subsequently the gel was fixed when
staining was satisfactory. After a final washing step the gel
was photographed in a Molecular Imager (BioRad,
Munich, Germany) and stored as TIFF files.
All batches were tested for purity by Western blot
(goat primary antibody: sc-122291; Santa Cruz, Heidelberg,
Germany) (Fig. 1C). Biotinylated antigoat secondary
antibodies (PK-6105) and avidin-alkaline phosphatase
complexes (AK-5000) were purchased from Vector Labo-
ratories (Burlingame) and used according to the manufac-
turer’s instructions. Final tagging was performed using
5-bromo-4-chloro-3-indolyl-phosphate and nitroblue tetra-
zolium (Sigma, Munich, Germany), yielding purple staining
of labeled bands.
To exclude endotoxin contamination, batches of
purified Gd were tested for TNF-a induction in PBMCs.
All samples were collected from patients who underwent
reduction for malignant ascites for medical reasons. The
local Ethics Committee approved the obtaining and
handling of all human material.
Monoclonal Antibodies and Flow Cytometry
Mouse antihuman monoclonal antibodies and the
appropriate isotype controls were purchased from Becton
Dickinson (Heidelberg, Germany): anti-major histo-
compatibility complex (MHC)-II (IgG2b), anti-CD86
(IgG1), anti-CD83 (IgG1), anti-CD14 (IgG2b),; and anti
DC-specific intercellular adhesion molecule 3-grabbing
nonintegrin (SIGN) (IgG2b). As there are no tested
antibodies commercially available for blocking experi-
ments, we combined, 3 antibodies, all of which were
polyclonal IgG goat antihuman (Santa Cruz Biotechnology,
Inc, Heidelberg, Germany) and applied them in an excess
concentration of 200 mg/mL. Two of these antibodies are
mapping for different epitopes near the C-terminus of Gd
of human origin [(C-15): sc-12291 and (Q-13): sc-12290].
The remaining antibody is mapping for an epitope near the
N-terminus. For fluorescence-activated cell sorting analysis,
105 DCs suspended in 100 mL phosphate-buffered saline
were incubated with 10 mL of fluorochrome-labeled mono-
clonal antibodies for 20 minutes on ice. After staining, the
samples were washed and analyzed immediately (FACS
Calibur; Becton Dickinson, Heidelberg, Germany). Data
were analyzed using CellQuest Pro software (version 5.2.1,
Becton Dickinson).
Endopinocytotic Activity
Cells were washed, and endopinocytotic activity
was assessed by adding fluorescein isothiocyanate (FITC)-
dextran (0.5mg/mL) (relative molecular weight 40,000) to
the culture medium for 30 minutes at 371C as described
previously.22 In brief, immature, untreated DCs were
incubated at 371C to serve as positive controls. On the
other hand, incubation on ice abrogates endopinocytosis
and was therefore used as a negative control. After
30 minutes, cells were washed 3 times to eliminate all
FITC-dextran attached to the outer cell membrane, and
incorporated FITC-dextran was subsequently analyzed by
flow cytometry.
Lymphoproliferative Activity
DCs were harvested and cocultured in complete
medium with a constant number of allogeneic nonadherent
PBMCs (2 105/200mL) in 96-well round-bottom micro-
titer plates at ratios ranging from 1:10 to 1:160. DNA
synthesis was measured using the ‘‘Cell Proliferation
ELISA, BrdU (chemiluminescent)’’ (Roche Diagnostics,
Mannheim, Germany). In short, proliferating cells incor-
porated 5-bromo-2-deoxyuridine (BrdU) in place of thymi-
dine over a 12-hour period. Cells were dried and fixed,
and the DNA was denatured. Subsequently, anti-BrdU
peroxidase-labeled antibody was added, and the immune
complexes were detected by a subsequent substrate reac-
tion. The reaction product was quantified by measuring the
light emission on a luminescent ELISA reader (MRX,
Dynatech Lab, Burlington) at 450 nm.
Cytokine Secretion
Cytokine secretion was analyzed by enzyme-linked
immunosorbent assay. The BD OptEIA Human IL-10 and
Human IL-12 (p40) enzyme-linked immunosorbent assay
sets were purchased from Becton Dickinson and used
according to manufacturer’s instructions. Cell culture
supernatants were collected 48 hours after stimulation,
stored at  201C, and subsequently analyzed.
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Statistical Analysis
Data are expressed as median±SEM. Statistical
significance was determined by the Student t test for paired
samples of original values. Differences were considered
statistically significant for P<0.05.
RESULTS
In vitro generated immature DCs were characterized
as being CD14 , CD83 , CD86 , and having an
intermediate expression of MHC class II and DC-SIGN.
To test the influence of Gd on their maturation processes,
DCs were incubated with 0.5mg/mL, 10mg/mL, or 25mg/mL
Gd over 24 hours, washed extensively, and subse-
quently matured using a standard combination of TNF-a
(1000U/mL) and IL-1b (10 ng/mL).6 Surface marker
expression was assessed by flow cytometry after 48 hours.
Upon maturation, untreated DCs showed the expected
increase in costimulatory and MHC-II molecules as well as
a reduced expression of DC-SIGN. However, DCs that
were subject to pretreatment with Gd had reduced
expression of costimulatory and MHC-II molecules as
compared with their stimulated counterparts (Fig. 2A).
Incubation with Gd alone without subsequent maturation
stimuli partially increased the expression of CD83 as well as
DC-SIGN, leaving CD86 and MHC-II expression un-
changed. In pretreated DCs, DC-SIGN mean fluorescence
intensity was between matured and immature DC inten-
sities. Interestingly, in dual parameter fluorescence-
activated cell sorting-analysis, the increase in CD83 in
Gd-pretreated DCs was caused by a CD83+/DC-SIGN+
double-positive population (Fig. 2B). To control for the
specificity of this effect we added 3 polyclonal antibodies
mapping for different epitopes of Gd in excess concentra-
tions to block Gd-specific effects. By these measures the
effect was partially reversible.
Similar results were obtained for DCs treated with
25 mg/mL Gd, whereas preincubating with 5mg/mL Gd had
only a marginal effect on the tested surface markers (data
not shown). However, no distinct DC-SIGN-positive DC
population was detected when preincubation was per-
formed with low concentrations of Gd (data not shown).
In all experiments, cell viability was assessed using
the Trypan-blue exclusion method and was comparable
between the different conditions and time points.
FIGURE 1. Isolation of Gd. High performance liquid chromatography (HPLC) profile with its ‘‘start’’ peak and the peak of isolated Gd.
Purity of the protein was verified by silver staining, which showed a protein band at 28 kDa. Western blot analysis of purified Gd with a
monoclonal antibody (A87-D /C5) verified the specificity of the isolate; MWM. Gd indicates glycodelin; MWM, molecular weight
marker.
FIGURE 2. Altered expression of maturation markers and
persistence of DC-specific intercellular adhesion molecule
3-grabbing nonintegrin (SIGN) after pretreatment with 10mg/mL
Gd. DCs were pretreated with 10mg/mL Gd for 24 hours and
subsequently matured with tumor necrosis factor (TNF)-a
(1000 IU/mL) and interleukin (IL)-lb (10ng/mL). Flow cytometry
for surface markers was performed after 48hours. Cumulative
data from 9 independent experiments are shown in A for all
nonblocking experiments. To control for specificity of the effect
3 blocking-experiments (indicated by a circled +) were performed.
Dots represent mean fluorescence index (MFI) of all experiments,
accompanied by the ± SEM. Conditions are marked by +/ as
appropriate. Density plots of a representative experiment are
depicted in B. DC indicates dendritic cells; Gd, glycodelin.
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Immature DCs constantly take up antigen and present
it via MHC molecules without concurrent costimulation.
Upon maturation, however, DCs down-regulate endopino-
cytosis and present their antigen content together with cost-
imulatory molecules in a stable fashion, which leads toward
immunostimulation.23 Treatment with Gd before applying
maturation stimuli nonsignificantly impaired down-regulation
compared with matured DCs. Incubation with Gd alone
did not change endopinocytosis in a significant manner;
only a marginal increase was noted compared with
unstimulated conditions. Adding polyclonal antibodies to
label Gd did not change this pattern (Fig. 3).
To further determine functional properties of Gd
pretreated and subsequently activated DCs, we assessed
their capacity to stimulate allogeneic lymphocytes. After
preincubating DCs with 10mg/mL Gd, lymphoproliferative
capacity was markedly diminished upon maturation as
compared with nonpretreated matured DCs (Fig. 4).
Pretreatment resulted in a 33% reduction of lympho-
proliferative activity. Treatment with Gd alone lead to a
25% increase of median BrdU+ lymphocytes compared
with immature DCs. When adding an excess amount of
polyclonal antibodies to block this effect, unstimulated DCs
retained most of their immature phenotype and lympho-
proliferative activity was only increased by 7%. In contrast,
pretreatment with Gd in combination with blocking
antibodies led to a decrease of lymphoproliferative activity
of 20% compared with mature DCs, that equaled a
blockage of 1=3 of the aforementioned effect (Fig. 4).
Upon activation with various stimuli, DCs produce
IL-12 and IL-10; this cytokine secretion pattern seems to
characterize their immunogenic behavior.24,25 TNF-a-
stimulated and IL-1b-stimulated DCs showed a median
IL-12 p40 secretion of 3403pg/mL (range: 2956 to 4302pg/mL)
and a median IL-10 secretion of 103 pg/mL (range:
85 to 142 pg/mL). This pattern changed toward an
IL-10-dominant cytokine milieu when Gd was added before
maturation. In this case, a median IL-12 p40 secretion of
1956 pg/mL (range: 1689 to 2235 pg/mL) was noted,
whereas IL-10 was detected at a median concentration of
357 pg/mL (range: 289 to 453 pg/mL). Low concentrations
of IL-10 were detected in both immature DCs [52 pg/mL
(range: 26 to 63 pg/mL)] and Gd-treated DCs without
subsequent maturation [98 pg/mL (range: 82 to 110 pg/mL)]
with only trace IL-12 p40 detectable in these conditions
(Fig. 5). Upon incubation with blocking antibodies the
IL-10 and IL-12 secretion-pattern of immature DC
resembled that of non-Gd preincubated conditions with
IL-10 at 118 pg/mL (range: 99 to 154 pg/mL). Matured DCs
that were preincubated with Gd, which was blocked with an
excess of polyclonal antibodies showed an IL-12 dominant
cytokine pattern [3758 pg/mL (range: 2984 to 4689 pg/mL)]
FIGURE 3. Incubation with 10mg/mL glycodelin (Gd) does not
alter endopinocytotic activity compared with matured or
unmatured counterparts, respectively. Dendritic cells were
incubated with fluorescein isothiocyanate-dextran at 371C for
30 minutes. Mean data from 9 experiments are shown for all
nonblocking experiments. Blocking experiments (indicated by a
circled +) were performed 3 times. Data show mean fluorescence
index (MFI). Error bars indicate SEM. Brackets with an asterisk
indicate statistical significance.
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FIGURE 4. Pretreatment with Gd reduces lymphoproliferative
activity despite of subsequent maturation. DCs were pretreated
with 10mg/mL Gd for 24 hours and subsequently matured with
tumor necrosis factor (TNF)-a (1000 IU/mL) and interleukin (IL)-lb
(10 ng/mL). DCs were harvested and cocultured with allogenic
peripheral blood monocytes. 5-bromo-2-deoxyuridine (BrdU)
incorporation was determined after 72 hour of coculture. The
data shown represent cumulative data from 9 experiments for all
nonblocking experiments. Blocking experiments (indicated by a
circled +) were performed 3 times. Error bars indicate ± SEM.
Data were normalized to stimulated DCs. DC indicates dendritic
cells; Gd, glycodelin.
FIGURE 5. Gd-pretreated matured DCs show an IL-10 dominant
pattern of cytokine secretion. DCs that were pretreated with
10mg/mL Gd before maturation with TNF-a (1000 IU/mL) and
IL-l b (10ng/mL) exhibit an IL-10high IL-12low cytokine pattern,
whereas incubation with Gd without subsequent maturation
does not induce IL-10. Maturation of DCs with TNF-a and IL-l
b alone resulted in an IL-10low IL-12high cytokine pattern. Mean
data of 6 independent experiments. Error bars indicate the SEM.
DC indicates dendritic cells; Gd, glycodelin.
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with a retained IL-10 activity of 186 pg/mL (range: 125 to
251 pg/mL). High Gd concentrations (25 mg/mL) did not
change this cytokine pattern, whereas this effect on cytokine
secretion was not statistically significant after pretreatment
with 5 mg/mL Gd (data not shown).
DISCUSSION
This study shows that monocyte-derived DCs exhibit
maturation defects upon incubation with the glycoprotein
Gd derived from ascites of ovarian cancer patients.
Isolated Gd from malignant ascites impaired full
expression of a mature phenotype as determined by flow
cytometric analysis. A fully matured surface marker pheno-
type (CD83+, CD86+, MHC-IIhigh, and DC-SIGNlow) was
induced upon maturation with a combination of TNF-a
and IL-1b, which is in agreement with published data.6,26
When we preincubated DCs with Gd, however, DCs
showed a different reaction to these standard maturation
stimuli. Compared with fully matured DC, we saw a
markedly reduced expression of costimulatory molecules,
which translated into an equally reduced immunostimulatory
capacity. MHC-II-dependent antigen presentation, indi-
cated by MHC-II expression, is not impaired by Gd
pretreatment, whereas DC-SIGN expression was partially
retained compared with mature DCs. DC-SIGN is
expressed by immature DCs and constitutes a potent
tolerogenic antigen-receptor that binds fucosylated
Lac-di-NAc-N-glycans with high affinity and contributes to
DC-mediated antigen-specific immunosuppression.27,28 A
‘‘semimature’’ DC pattern has been reported to be
characteristic of tolerogenic behavior.29 Interestingly, we
saw a distinct CD83+/DC-SIGN+ population, that is
indicative of a tolerogenic phenotype. DC-SIGN is a type II
C-type lectin that binds with high affinity distinct carbo-
hydrates such as high mannose structures and fucosylated
Lewis blood group antigens (eg, Lewisx); fucosylated Lac-
di-NAc-N-glycans is bound with the highest affinity.28,30,31
All of these DC-SIGN binding partners are found on Gd.32
Gd is the only mammalian glycoprotein that carries the
strongest DC-SIGN binding partner, which is otherwise
only found on helminths such as Schistosoma mansonii.33
Lac-di-NAc-N-glycans seem to play a central functional
role in the immunogenicity of DCs. Schistosoma egg
antigen (SEA)-expressing Lac-di-NAc-N-glycans inhibit
DC maturation and skew subsequent immune responses
toward a tolerogenic pattern.34 Van Liempt et al,34 (2007)
show in their experiments a DC-SIGN-dependent reduction
in IL-12 p40 secretion in matured DCs upon incubation
with SEA, whereas IL-10 secretion remains high even with
low concentrations of SEA. These results are in striking
similarity to the effects we see with ovarian cancer-derived
Gd, although we were not able to demonstrate DC-SIGN-
dependence owing to the scarceness of isolated Gd. One
of the decisive factors discriminating immunostimulatory
from tolerogenic DCs is their cytokine pattern. DCs secrete
IL-12, one of the pivotal cytokines that induce a cytotoxic
T-cell immune response, upon various maturation stimuli.35
In contrast, DCs produce IL-10, the hallmark cytokine
involved in tolerogenic immune responses, upon exposure
to inhaled antigens, thereby inducing peripheral tolerance
and inhibiting misled immune responses such as asthma.36
Recent studies that examined cancer antigen recog-
nition showed an increased IL-10 production when DCs
encounter necrotic cancerous material.37 We were able to
demonstrate that IL-10 was secreted in response to a single
cancer-derived glycoprotein, Gd. There is conflicting
evidence on whether Gd induces monocytic apoptosis.38,39
However, IL-10 secretion, which we saw in our experi-
ments, argues against a direct cytopathic effect of Gd on
DCs. Moreover, we assessed viability by Trypan dye
exclusion, leading toward comparable results at the Gd
concentrations used. As a reproductive tract glycoprotein,
Gd has been used to stimulate monocytes derived from the
uterine deciduas.40 Gd was able to induce a similar cytokine
pattern in our experiments using monocyte-derived DCs
from peripheral blood of healthy volunteers compared with
decidual monocytes. These decidual monocytes are known
to play a central role in tolerogenic mechanisms during
pregnancy, when the semiallogenic fetus is accepted by the
maternal immune system.41 Furthermore, spontaneous
secretion of tolerogenic cytokines, including IL-10, has
been reported for mononuclear cells during the course of
pregnancy.42 Most importantly, DCs were less able to
stimulate allogeneic lymphocytes upon encounter of Gd.
Peripheral tolerance is one of the central features of an
immune response during carcinogenesis and pregnancy.43,44
In our experiments, we provide morphologic and functional
data that a tolerogenic DC state is induced by ovarian
cancer-derived Gd, a mechanism that is also employed
during early pregnancy. Targeting DCs, this mechanism
influences one of the central players of adaptive immunity
in a way that supports carcinogenesis. As DCs are
employed in various immunotherapy protocols, these data
might influence strategies in which whole tumor cell-derived
antigen preparations are used to load DCs. In these
instances, tolerogenic mechanisms that hamper anticancer
immune responses might be induced. Our data contribute
to a better understanding of the interactions between
tumors and the immune system and may lead to more
effective cancer immunotherapy strategies.
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Ovarian cancer Gd induces a tolerogenic phenotype in
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